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 Introduction 
 
1 
 
 End Stage Renal Disease (ESRD) is defined as the near failure or 
failure of the kidneys to perform their normal functions like, excretion; 
maintenance of acid-base, fluid and electrolyte balance and the synthesis of 
hormones such as erythropoietin and renin
1
.  
 End Stage Renal Disease (ESRD) is the final stage of chronic kidney 
disease (CKD) and ESRD usually results from a progressive and irreversible 
loss of renal function and is defined by a glomerular filtration rate (GFR) of 
less than 15 ml/min. In Chronic Kidney Disease (CKD), the pre-End stage 
renal disease is termed as Non End Stage Renal Disease (NESRD) or Non-
dialysis dependent CKD (NDD-CKD)
1
  
 The most common causes of ESRD are chronic hypertension, 
glomerulonephritis, polycystic kidney disease, renovascular disease and 
diabetes mellitus.
2
 
 The term “Diabetes Mellitus” is used to identify a group of disorders 
characterized by elevated levels of glucose in the blood. This elevation is 
the result of a deficiency in insulin secretion or an increased cellular 
resistance to the actions of insulin, leading to a variety of metabolic 
abnormalities involving carbohydrates, fats and proteins
3
.  
 A number of pathological mechanisms related to elevated levels of 
glucose in the blood have been defined, including the activation of the 
sorbitol pathway, the formation of advanced glycation end-products 
(AGEs), the damaging effect of oxidative stress and altered lipid 
metabolism. These mechanisms have been associated with classical clinical 
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complications of Diabetes Mellitus such as retinopathy, nephropathy, 
neuropathy, macrovascular disease and poor wound healing
4,5
. 
Diabetes mellitus is a major health problem in today’s society as the 
number of patients with Diabetes is growing continuously. Globally, by the 
year 2010 more than half of the world’s diabetics will be Asians6,7. 
Patients with ESRD can rely on kidney replacement therapeutic 
modalities such as haemodialysis (HD), peritoneal dialysis (PD) or renal 
transplantation (NTx). Although kidney replacement therapies have proven 
to be successful in prolonging the life expectancy of ESRD patients, several 
limitations and long-term complications exist
8,9
 .Since the majority of 
haemodialysis patients has no residual urine output, they have to maintain a 
fluid restricted diet to prevent fluid overload and are thus allowed to 
consume only approximately 500 mL per day
10
 .If patients do not adhere to 
the restriction in fluid intake, (chronic) fluid overload may occur, which can 
result in hypertension, acute pulmonary oedema, congestive heart failure 
and consequently death
11,12
 . 
As Diabetic Nephropathy progresses to End-Stage Renal Disease 
(ESRD) and impose enormous medical, economic and social costs on both 
the patient and the health care system, it deserves greater social concern. In 
fact, Diabetic Nephropathy has become the major cause of ESRD
13 
The population with End-Stage Renal Disease (ESRD) in the United 
States is composed of more than 200,000 patients who undergo dialysis and 
70,000 patients with functioning kidney transplants. With the prevalence of 
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ESRD growing at a rate between 7 to 9 percent per year, it is projected that 
there will be more than 350,000 such patients by the year 2010.
14
  
Hence it is felt the need to identify the disease at an early stage based 
on the oral manifestation in NESRD- Diabetes Mellitus patients to avoid the 
complication and for suitable treatment, so a study has been undertaken to 
detect the oral manifestation in already diagnosed ESRD-Diabetes Mellitus 
and NESRD-Diabetes Mellitus patient and to compare them in both the 
conditions. 
 Aims & Objectives  
  
4 
 
AIM OF THE STUDY: 
To assess oral signs, symptoms and oral lesions type and prevalence, 
in diabetic patients with End Stage Renal Disease (ESRD-DM) and compare 
them with analogous findings in Non-End Stage Renal Disease             
(NESRD-DM) group. 
OBJECTIVE OF THE STUDY: 
1. To compare the oral signs, symptoms and oral lesions type and 
prevalence in diabetic patients with End Stage Renal Disease 
(ESRD-DM) and with Non-End Stage Renal Disease (NESRD-DM) 
group 
2. To analyze the possible association between oral manifestation as 
well as with relevant laboratory findings 
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DIABETES MELLITUS 
DEFINITION 
 Diabetes Mellitus is a clinical syndrome comprising a heterogeneous 
group of metabolic diseases that are characterized by chronic hyperglycemia 
and disturbances in carbohydrate, fat and protein metabolism secondary to 
defects in insulin secretion, insulin action or both.
15 
 The World Health Organization (WHO) has considered Diabetes 
Mellitus a public health problem since 1975. Therefore, it is necessary that 
health care professionals become interested on the disease in order to 
provide an appropriate treatment to these patients in the different fields of 
knowledge
15
. 
 Diabetes is a dangerous disease since the patient’s and healthcare 
promoter’s negligence may impair the patient’s quality of life and even lead 
the patient to death. Diabetes is a disease in which the insulin’s regulatory 
activity is defective. This can be a result of decreased amount of insulin that 
should be secreted, total absence of insulin secretion or the production of 
antibodies against insulin causing its destruction before it can act in the 
different areas of the body. In the first two cases there is degeneration or 
inactivation of beta cells of the Langerhans islets which produce insulin. In 
the last case, the amount of insulin secreted may be normal but it does not 
reach its destination
15
. 
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WHO-Criteria for the Diagnosis of Diabetes: 
1. Symptoms of Diabetes plus casual venous plasma glucose more than 
or equal to11·1 mmol/l. Casual is defined as any time of day without 
regard to time since last meal. The classic symptoms of diabetes 
include polyuria, polydipsia, polyphagia and unexplained weight 
loss 
2. Fasting plasma glucose more than or equal to 7·0 mmol/l or whole 
blood than or equal to 6·1 mmol/l. Fasting is defined as no calorie 
intake for at least 8 hours 
3. Two hour plasma glucose more than or equal to 11·1 mmol/l during 
oral glucose tolerance test using 75 g glucose load  
In the absence of symptoms, these criteria should be confirmed by 
repeat testing on a different day. If the fasting or random values are not 
diagnostic, the 2 hour value post-glucose load should be used 
Note: 
 Fasting plasma glucose less than 6·1 mmol/l—normal 
 Fasting plasma glucose more than or equal to 6·1 and less than 7·0 
mmol/l —impaired fasting blood glucose 
 Fasting plasma glucose more than or equal to 7·0 mmol/l—
provisional diagnosis of Diabetes; the diagnosis must be confirmed
5
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CLASSIFICATION OF DIABETES MELLITUS 
 In 1997, the American Association of Diabetes proposed a 
classification system for diabetes based on its etiology. Therefore, diabetes 
is currently classified as:  
 Type 1 or Juvenile Diabetes or IDDM –Insulin Dependant 
Diabetes Mellitus  and  
 Type 2 or Acquired Diabetes or NIDDM - Non Insulin 
Dependant Diabetes Mellitus  
 Type 1 Diabetes was defined as onset of Diabetes before 35 years of 
age and insulin treatment initiated within one year of diagnosis of Diabetes.  
 Type 1 Diabetes it appears in the first or second decade of life; it is 
caused by the destruction of pancreatic beta cells, which can be caused by a 
viral or an autoimmune process leading to a blockade in the production of 
insulin
16
.  
 On the other hand, Type 2 Diabetes is the result of an abnormality 
that can occur both at the molecular level of insulin and at the cellular level 
of insulin receptors
15
. 
Rivera
17
 suggested that the appearance of Alzheimer disease may be 
associated with a new type of Diabetes named Type 3 Diabetes. Although 
the pancreas is the main organ responsible for insulin secretion, the fall of 
insulin levels in the brain causes the so-called Type 3 Diabetes. In this study 
it was found that the brain produces a small amount of insulin and proteins. 
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The fact that there is an appropriate level of insulin as well as the correct 
activity of the receptors is described as vital for the cell survival in the brain.
 
It is estimated that there are about 170 million people with Diabetes 
Mellitus in the world and approximately 10 million in Brazil. Of those, 
approximately 50% do not know they have the disease. According to the 
WHO, about 7% of the world adult population has Diabetes. In the state of 
São Paulo this rate reaches 9.6%
15
. 
Paradella et al
18
 stated that the main symptoms of the patient with 
Diabetes Mellitus are polydipsia, polyuria-nocturia, polydipsia associated 
with xerostomia, polyphagia, vulvar pruritus, rapid weight loss, even with a 
balanced diet. Visual changes (such as blurred vision), somnolence, pain, 
cramps, fatigue, tingling and numbness of lower limbs, asthenia, organ 
deficiency, indisposition to work, discouragement, generalized physical and 
mental tiredness, ketoacidosis and fruit breath are also observed. 
 To meet cellular energy needs, fat is broken down through lipolysis, 
releasing glycerol and free fatty acids. Glycerol is converted to glucose for 
cellular use. Fatty acids are converted to ketones, resulting in increased 
ketone levels in body fluids and decreased hydrogen ion concentration (pH). 
Ketones are excreted in the urine, accompanied by large amounts of water. 
The accumulation of ketones in body fluids, decreased pH, electrolyte loss 
and dehydration from excessive urination, and alterations in the bicarbonate 
buffer system result in Diabetic Ketoacidosis (DKA). 
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Diabetic ketoacidosis (DKA) is a potentially life-threatening 
complication in patients with Diabetes Mellitus. It happens predominantly in 
those with Type 1 Diabetes, but it can occur in those with Type 2 
Diabetes under certain circumstances. DKA results from a shortage 
of insulin; in response the body switches to burning fatty acids and 
producing acidic ketone bodies that cause most of the symptoms and 
complications
19
.  
Untreated DKA can result in coma or death. Many patients with 
Type 1 Diabetes are initially diagnosed with the disease following a hospital 
admission for DKA. In a known Diabetic patient, periods of stress or 
infection may precipitate DKA. More often, however, DKA results from 
poor daily glycemic control. Patients who remain severely hyperglycemic 
for several days or longer due to inadequate insulin administration or 
excessive glucose intake are prone to develop DKA.
20 
Blood samples are usually taken to measure urea and 
creatinine (measures of kidney function, which may be impaired in DKA as 
a result of dehydration) and electrolytes
19
. 
A 2006 American Diabetes Association statement (for adults) 
categorizes DKA into one of three stages of severity
19
: 
 Mild: blood pH mildly decreased to between 7.25 and 7.30 (normal 
7.35–7.45), serum bicarbonate decreased to 15–18 mmol/l (normal 
above 20), the patient is alert 
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 Moderate: pH 7.00–7.25, bicarbonate 10–15, mild drowsiness may 
be present 
 Severe: pH below 7.00, bicarbonate below 10, stupor or coma may 
occur 
Type 2 Diabetes Mellitus patient taking metformin may develop lactic 
acidosis as a side-effect of their medication
19
 
In regards to the specific role of Otorhinolaryngology, Scherer and 
Lobo
21
 noticed irritative vestibular disorder in patients with Type I Diabetes. 
Maia and Campos
22
 state that there is evidence that Diabetes Mellitus may 
cause hearing loss. 
REVIEW OF LITERATURE FOR DIABETES MELLITUS 
According to Tommasi
23
, the most common oral manifestations in 
Diabetic patients include xerostomia, burning and eventual erythema, 
ulcerations, pharyngeal infections caused by Candida albicans, cheilitis, 
lichen planus, tumefaction of salivary glands, gingival problems, 
periodontal problems, abscesses and marked loss of alveolar bone, although 
none of them is a pathognomonic lesion. In the patient with uncontrolled 
Diabetes, a decreased response to infection (bacterial, fungal and viral) is 
observed, due to the hyperglycemia and ketoacidosis that changes the 
phagocytosis of macrophages and the chemotaxis of polymorphonuclear 
neutrophils. The patient with controlled Diabetes without vascular disease 
does not present increased rates of infection since a good control of the 
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disease reduces the likelihood of infection to a minimum, and repair does 
not seem to be very different from that seen in the Non-Diabetic patient. In 
1993, the WHO included the periodontal disease as a classic complication of 
Diabetes. 
Löe
3
 proposed that periodontal disease was the sixth complication of 
Diabetes Mellitus.  
Ship
5
 listed dental caries, salivary dysfunction, oral mucosal 
diseases, oral infections such as candidiasis, taste and other neurosensory 
disorders. Furthermore, a reduction in salivary flow has been reported in 
people with Diabetes who have neuropathy and diminished salivary flow is 
a risk factor for dental caries. 
 
Moore PA et al
24
 found that Dry mouth, or xerostomia, has been 
reported in people with Diabetes Mellitus. Salivary flow may be affected by 
a variety of conditions, including the use of prescription medications and 
increasing age, and it appears to be affected by the degree of neuropathy and 
subjective feelings of mouth dryness that may accompany thirst. These 
variables are relevant for adults with Diabetes Mellitus. Therefore, although 
no definitive association of Diabetes and reduced salivary flow has been 
identified, this complication has been reported in people with Diabetes. A 
number of types of oral mucosal lesions, including lichen planus and 
recurrent aphthous stomatitis have been reported in people with Diabetes 
Mellitus. Not all study results have showed this association, and these are 
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relatively common disorders that often are observed in patients who do not 
have Diabetes.  
Guggenheimer J et al
25
, conducted a cross-sectional study, 
compared the prevalence of candidiasis in 405 subjects with IDDM and 268 
nondiabetic control subjects and found that oral candidiasis has been a more 
consistent finding in patients with Diabetes (15.1%). Candidiasis is a 
manifestation of an immunocompromised state, and a reduction in salivary 
flow is another risk factor for oral candidiasis (P <0.0001).  
Taste disturbances have been reported in patients with Diabetes Mellitus but 
all investigators have not observed this finding. Although patients with 
Diabetes who receive hemodialysis have been reported to have altered taste 
it is a complex symptom, and it may be related to salivary flow and changes 
in food intake associated with disease management. Other neurosensory 
disorders of the oral and perioral tissues, including burning mouth syndrome 
and dysphagia, have been reported in patients with Diabetes  
 Tommasi
23
, Sousa et al
26
, Yuli Muller and Yuraima
27
, observed a 
high frequency of Candida infections in patients with Diabetes Mellitus. The 
clinical manifestations and the oral symptoms of Diabetic patients may vary 
from a minimum to a more aggressive stage and depend on the type of 
existing hyperglycemic abnormality, of treatment control and the time 
elapsed since the diagnosis of the disease. 
 Belmiro Cavalcanti do Egito Vasconcelos et al
28
 conducted a study 
on 30 patients diagnosed as diabetes, 9 (30%) were males and 21 (70%) 
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females. Of the studied patients, 40% were below 60 years of age, and 60% 
were older than 60 years. Thirteen different types of mucosal alterations 
were diagnosed. Tongue varicose veins (36.6%) and candidiasis (27.02%) 
were the most prevalent. Such alterations can be associated with the fact that 
these conditions are commonly found in senile patients and are also 
associated with prolonged wear of dentures. Xerostomia was diagnosed in 
only 1 (3.33%) patient,  
DIABETIC NEPHROPATHY 
DEFINITION 
Diabetic Nephropathy is a clinical syndrome characterized by 
persistent albuminuria, elevated arterial blood pressure, a ceaseless decline 
in glomerular filtration rate (GFR) and a high risk of cardiovascular 
morbidity and mortality
29,30
. It is progressive and usually irreversible.  
The natural history of Diabetic Nephropathy is complex and most 
changes in the kidneys are currently undetectable in clinical practices
31
. 
Renal involvement in Diabetes is presumed to be resulted from the interplay 
between several metabolic and homodynamic processes 
32,33
. 
In brief, Diabetic Nephropathy is morphologically featured by either 
diffuse or selective expansion of the mesangial matrix, which leads to 
obliteration of capillary lumen and loss of filtration surface area. Clinically, 
microalbuminuria is the hallmark of Diabetic Nephropathy and accounts for 
subsequent progressive renal dysfunction among Diabetes people
34
. With no 
therapeutic intervention, serum creatinine levels continue to climb and 
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patients go on to develop ESRD eventually
35
. Patients with Diabetes with 
the highest GFR early in the course of their disease are found very likely to 
develop Diabetic Nephropathy
36,37
 . It is mainly seen in Type 1 Diabetic 
patients, but also probably noted in those with Type 2. 
Diabetic Nephropathy is the most common cause of End-Stage 
Renal Disease requiring dialysis in the US 
38
. The incidence of Diabetic 
Nephropathy in this country has increased substantially over the past few 
years. Advanced Diabetic Nephropathy is also the leading cause of 
glomerulosclerosis and End-Stage Renal Disease worldwide 
39
. Between 
20% and 40% of patients with Diabetes ultimately develop nephropathy, 
although the reason why not all patients with Diabetes develop this 
complication is unknown.
40 
The natural history of Diabetic Nephropathy differs according to the 
type of Diabetes and whether microalbuminuria (defined as more than 30 
mg but less than 300 mg albumin in the urine per day) is present. If 
untreated, 80% of people who have Type 1 Diabetes and microalbuminuria 
will progress to overt nephropathy (i.e. proteinuria characterized by more 
than 300 mg albumin excreted daily), whereas only 20-40% of those with 
Type 2 Diabetes over a period of 15 years will progress
40
. 
Nielsen
41
 demonstrated more than a decade ago, a clear, early 
predictor of disease progression is increasing systolic blood pressure, even 
within the prehypertensive range. Among patients who have Type 1 
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Diabetes with nephropathy and hypertension, 50% will go on to develop 
End-Stage Renal Disease within a decade. 
Mortality among dialysis patients with Diabetes is 22% higher in the 
first year following the initiation of dialysis and 15% higher at 5 years than 
that among dialysis patients without Diabetes 
42
. 
Diabetic Nephropathy has several distinct phases of development. 
Functional changes occur in the nephron at the level of the glomerulus, 
including glomerular hyper filtration and hyper perfusion, before the onset 
of any measurable clinical changes. Subsequently, thickening of the 
glomerular basement membrane, glomerular hypertrophy, and mesangial 
expansion take place
43
.  
  Steinke
44
 demonstrated that individuals with Type 1 Diabetes and 
microalbuminuria in whom these histological alterations were detected were 
destined to progress to overt nephropathy. 
Microalbuminuria, however, has a variable course; its progression to 
macroalbuminuria (> 300 mg per day) is unpredictable and does not always 
lead to development of nephropathy
35
. Moreover, the rate of kidney function 
decline after the development of nephropathy is highly variable between 
patients and is influenced by additional factors, including blood pressure 
and glycemic control. 
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The Progression of Diabetic Nephropathy occurs in five stages
40 
The Stage 1 Diabetic Nephropathy (normal) is characterized by:  
 Albuminuria is less than 20 mg in 24 hours  
 Glomerular filteration rate is high or normal hyperfilteration 
 Serum Creatinine level is 60-100 µmol/l 
 The blood pressure is normal 
 There is no clinical signs 
The Stage 2 Diabetic Nephropathy is characterized by: 
 Albuminuria is between 20- 300 mg in 24 hours  
 Glomerular filteration rate is  normal or high   
 Serum Creatinine level is 60-120 µmol/l 
 The blood pressure is slightly increased 
 There is no clinical signs 
 This stage is called as Incipient Diabetic Nephropathy 
The stage 3 Diabetic Nephropathy is characterized by: 
 Albuminuria is more than or equal to 300 mg in 24 hours   
 Glomerular filteration rate is normal or decreased  
 Serum creatinine level is 80-120 µmol/l  
 The blood pressure is increased 
 The clinical signs includes anaemia with or without oedema  
 This stage is called as Persistent Diabetic Nephropathy 
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The stage 4 Diabetic Nephropathy is characterized by: 
 Albuminuria is more than or equal to 300 mg in 24 hours   
 Glomerular filteration rate is decreased  
 Serum creatinine level is 120- 400 µmol/l  
 The blood pressure is increased 
 The clinical signs includes anaemia with or without oedema  
 This stage is also called as Clinical Diabetic Nephropathy 
The stage 5 Diabetic Nephropathy is characterized by: 
 Albuminuria is more than or equal to 300 mg in 24 hours   
 Glomerular filteration rate is greatly decreased  
 Serum Creatinine level is very high ,more than 400 µmol/l  
 The blood pressure is increased 
 The clinical signs includes anaemia with or without oedema, and 
uremic symptoms can also be seen  
 This stage is also called as End Stage Diabetic Nephropathy40 
The accumulation of creatinine and blood urea nitrogen (BUN), 
waste products in the blood is called Azotemia. Early detection of Azotemia 
is vital to preserve kidney function and to delay or prevent ESRD. 
According to the National Institute of Diabetes & Digestive & Kidney 
Diseases, individuals with Type 2 Diabetes may remain in this stage for 
several years
38
. 
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Stage V, or ESRD, is when the kidneys fail to function, the GFR 
severely decreases, and hypertension continues to worsen. During this final 
stage, the kidneys cannot excrete toxins; maintain fluid, pH, and electrolyte 
balances; or secrete important hormones (renin, vitamin D, and 
erythropoietin) 
45
. 
DEFINITION AND CLASSIFICATION OF RENAL DISEASE 
In 2002, the National Kidney Foundation’s Kidney Disease Outcomes 
Quality Initiative (KDOQI) introduced a conceptual model for the definition 
and classification of chronic kidney disease.
1
 The model included 
antecedents associated with increased risk for development of chronic 
kidney disease, earlier stages of disease that could progress to later stages or 
lead to complications, and kidney failure as the end stage . Chronic kidney 
disease was defined based on the presence of kidney damage or glomerular 
filtration rate (GFR <60 ml/min per 1.73m
2
) for less than or equal to 3 
months, irrespective of cause, and was classified into five stages based on 
the level of GFR.
1 
1. Stage 1 condition characterized by kidney damage with normal or 
increased GFR i.e., GFR ≥ 90 mL/min/1.73m2 
2. Stage 2 condition characterized by kidney damage with mild 
decrease in  GFR i.e., GFR is between 60- 89 mL/min/1.73m
2
 
3. Stage 3 condition characterized by kidney damage with moderate 
decrease in GFR i.e., GFR is between 30-55 mL/min/1.73m
2
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4. Stage 4 condition characterized by kidney damage with severe 
decreased in GFR i.e., GFR is between 15-25 mL/min/1.73m
2
 
5. Stage 5 condition is characterized by kidney failure i.e., GFR is < 15 
mL/min/1.73m
2
 
End-Stage Renal Disease is defined as stage 5 of chronic kidney 
disease i.e., it appears when GFR decreases to <5-10 mL/min/1.73 m
2
. At 
this point the patient is seriously ill, with pronounced uremic symptoms. 
High blood pressure, weight loss, anemia, neuropathy and osteodystrophy 
indicate that the patient needs to start dialysis treatment. Normal change in 
GFR values is usually measured by creatinine clearance (CC), which gives 
an acceptable approximation of the value of GFR
46
.  
The glomerular filtration rate (GFR) is traditionally considered the 
best overall index of renal function in health and disease. Because GFR is 
difficult to measure in clinical practice, most clinicians estimate the GFR 
from the serum creatinine concentration
47
.   
Serum and urine creatinine were measured by using a kinetic 
alkaline picrate assay or Serum creatinine was determined at a central  
laboratory by a kinetic Jaffe reaction using a Hitachi 911 E analyzer 
(Boehringer Mannheim, Mannheim, Germany),with a normal range in 
serum of 62 to 124 mmol/L (0.7 to 1.4 mg/dL)
47
 . 
At any given GFR, the serum creatinine concentration is 
significantly higher in men than in women and in black persons than in 
white persons 
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Patients with a serum creatinine concentration of 124 mmol/L (1.4 
mg/dL), a value within the normal range in many clinical laboratories, 
would have renal insufficiency, as defined by serum creatinine 
concentration, creatinine clearance, or GFR less than two standard 
deviations below the normal range
47
. Patients with a serum creatinine 
concentration of 354 mmol/L (4.0 mg/dL) would be approaching end-stage 
renal disease, as defined by a GFR less than 10 mL/min per 1.73 m
2
. 
 Normal values of serum Cr are 0.5-1.4 mg/dl; in patients with renal 
insufficiency, Cr will be of 1.5 mg/dl or more. Plasmatic creatinine can be 
related to creatinine clearance using several formulas, such as Cockcroft-
Gault or MDRD (modified diet in renal disease formula)
1
. 
Cockcroft-Gault equation estimates creatinine clearance (Cc), 
Where Pcr is plasma creatinine:  
Creatinine clearance (Cc) = 
 
MDRD (modified diet in renal disease formula) estimates GFR  
(Where Pcr is plasma creatinine, SUN is serum urea nitrogen, and Alb is 
albumin): 
GFR = 170 X (Pcr)
-0.999
 X (Age)
-0.176 
X (SUN)
-0.017
(Alb) 
+0.318
 X (0.762 if 
patient is female) X (1.180 if patient is black) 
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Presently, the classification of chronic renal disease is guided by the 
National Kidney Foundation’s K-DOQI guides (The National Kidney 
Foundation Kidney Disease Outcomes Quality Initiative) of 2002, which 
include the following situations: 
 Kidney damage during at least 3 months with or without a decrease 
in glomerular filtration rate 
 Filtration rate < 60 ml/min/1.73 m2 during more than 2 months with 
or without kidney damage 
1
. 
End-Stage Renal Disease (ESRD) is that stage of kidney impairment 
which is irreversible, cannot be controlled by conservative management 
alone, and requires dialysis or kidney transplantation to maintain life. 
There are two types of kidney failure
1
: acute and chronic. 
1. Acute kidney failure is a temporary decline in kidney function that can 
most often be corrected. 
2. Chronic kidney failure, on the other hand, is a permanent condition, 
meaning that once it occurs, the kidneys cannot be made to function 
again. 
Chronic kidney failure may be the result of heredity, as with polycystic 
kidney disease, or may be caused by prolonged medical conditions, such as 
high blood pressure or diabetes. Persons with chronic renal failure are 
referred to as having end-stage renal disease
1
. 
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THE DEVELOPMENT OF KIDNEY DISEASE 
For many years glomerulonephritis has been the most common 
disease for patients on dialysis. The incidence of Diabetes Mellitus (DM) is 
now increasing fast and will soon result in the most common diagnosis in 
dialysis treatment. When a systemic disease affects the kidneys it is referred 
to as secondary. 
Patients with diabetes are by far the largest group; 25-45% develops 
a diabetic nephropathy. Irrespective of whether the diabetes is type 1 or 2, a 
majority of the individuals can be detected early because of 
microalbuminuria, which is a sign of poor prognosis. Consequently 
glomerulosclerosis and atherosclerosis appear and GFR gradually declines, 
leading to end-stage renal disease.
46 
About one-fifth of diabetic patients develop End-Stage Renal 
Disease (ESRD) during their lifetime. Diabetes is currently the major cause 
of renal failure requiring dialysis treatment or renal transplantation in the 
US, Europe, and Japan, and its incidence is rapidly increasing in all 
countries, leading  to the definition of Diabetic Nephropathy as ‘a medical 
catastrophe of worldwide dimensions’ 48 
Although rates of dialysis initiation and of renal transplantation are 
readily available in Europe and the US, this information only approximates 
the true incidence and prevalence of ESRD, because the definition of ESRD 
and the criteria for dialysis initiation might differ across countries.
48 
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RISK FACTORS FOR DEVELOPMENT OF CKD
49 
● Underlying disease: 
 Hypertension 
 Diabetes 
 Dyslipidemia 
● Lifestyle factors: 
 Tobacco 
 Inactivity 
● Family history 
● Aging 
● Prenatal factors: 
 Maternal Diabetes Mellitus  
 Low birth weight 
 Small-for-gestational-age status 
Chih-Cheng Hsu et al
50 
performed a study that  included 6,001 
subjects, and  found that the prevalence of CKD stages 3 to 5 in Taiwan is 
6.9% (95% confidence interval, 4.4 to 9.4). Awareness rates for CKD in 
Taiwan are low: 8.0% for individuals with stage 3, 25.0% for those with 
stage 4, and 71.4% for those with stage 5. Awareness rate is related closely 
to serum creatinine level: those with creatinine levels greater than 1.6 mg/dL      
(>141 μmol/L) are more likely to be informed of having a kidney disease 
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Sanjay Kumar Agarwal et al
51 
stated that a Serum Creatinine 
>1.8mg% as renal failure. They suggested a repeat test for Serum Creatinine 
which was done after 8–12 weeks to confirm chronicity of renal failure. If it 
was >1.8mg% after 3 months in the absence of reversible factors, CRF was 
diagnosed. 
MEDICAL MANAGEMENT: 
Use of Antihyperglycemic Agents in Patients with Renal Failure
52 
Metformin is contraindicated in renal failure because of the 
associated risk for lactic acidosis. It can be used at low dosages up to a 
creatinine clearance of 30 to 60 ml/min and should be avoided with 
clearances less than 30. Although the metabolism of thiazolidinediones is 
unaffected by renal failure, they must be used with caution in this context 
because of their volume retaining effect with a risk for heart failure. 
 The sulfonylureas (glyburide, gliclazide, glipizide, glibenclamide, 
tolbutamide, and chlorpropamide) have increased potency as the renal 
function decreases and are contraindicated in severe renal failure. The 
nonsulfonylurea insulin secretagogues repaglinide and nateglinide can be 
used in renal failure without dose adjustments. α-Glucosidase inhibitors 
(acarbose and miglitol) are contraindicated in renal failure
52
. 
a) Patient with renal disease in conservative medical treatment52:  
For the dental treatment of these patients, good communication with their 
nephrologist is highly recommended, in order to be aware of the stage of the 
pathology suffered and the treatment prescribed. Before any invasive dental 
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procedure, possible hematologic problem in the patient should be studied. It 
is essential to remove any infective foci as soon as possible. Due to the 
frequent hypertension, blood pressure should be monitored during the 
procedures. When prescribing drugs, those that are nephrotoxic must be 
avoided (tetracyclines, aminoglycosides), some of them need a dose 
adjustment (as previously detailed). Apart from these considerations, no 
more exceptional measures must be performed
52
. 
b) Patient with renal disease in peritoneal dialysis:  
In cases of peritoneal dialysis, a catheter placed in the abdominal wall and 
inserted in the peritoneum achieves access to the body, in order to remove 
nitrogen and other metabolic toxic products; through this, a hypertonic 
glucosated solution is introduced. Peritoneal membrane of the patient filters 
blood waste products by means of an osmotic mechanism, so they would be 
transferred to the electrolytic solution and then evacuated to the exterior 
53
. 
This form of dialysis can be performed at home, but must be done every 
day. These patients do not require special measures with regard to dental 
treatment, apart from the considerations already mentioned 
54
. 
c) Patient with renal disease in hemodialysis:  
In hemodialysis, the filtering process is carried out by a machine (dialyzer), 
outside the patient’s body. Most of these patients receive this treatment        
3 times a week. In order to take the blood out of the body and to return it, it 
is necessary to have a vascular access. Permanent access is obtained by 
surgically connecting an artery to a vein, using a blood vessel (arteriovenous 
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fistula) or a synthetic bridge (arteriovenous graft).
55
 A special solution 
(dyalisate) corrects the chemical disturbances and impurities of the blood, 
which is then introduced into the body . During the process of hemodialysis, 
the patient’s blood is anticoagulated with heparin to facilitate blood transit. 
For this reason, dental treatments with a risk of bleeding must not be 
performed the day of hemodialysis
56
. If an emergency dental treatment must 
be performed, protamine sulphate (heparin antagonist) can be administered 
to block the anticoagulant effect. However, bleeding tendency would be still 
present due to platelet dysfunction and anemia, so usual hemostatic 
measures must be carried out
57
. There is a risk of infection because of the 
vascular access, and of transmission of HBV, HCV and HIV, so this must be 
confirmed in patients receiving hemodialysis
58
.  
Capillary blood glucose and the insulin flow rate were recorded 
every 30 min. Five milliliters of venous blood were collected for the 
measurement of blood urea nitrogen and serum creatinine immediately 
before and after the session. Blood urea nitrogen and serum creatinine were 
determined on venous blood samples collected immediately before and at 
the end of the hemodialysis session using colorimetric methods. The quality 
of dialysis was calculated as the logarithm of the ratio of serum urea 
concentrations at the beginning and at the end of hemodialysis
59
. 
Creatinine failure was defined as a serum creatinine value greater than      
2.0 mg/dl
60 
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Dental Management of the patient receiving hemodialysis patients depends 
on the stage of dental procedure 
61 
1. Before treatment  
 Determine dialysis schedule and treat on the day after dialysis. 
 Consult with patient’s nephrologist for recent laboratory tests and 
discussion of antibiotic prophylaxis. 
 Identify arm with vascular access and type; notate in chart and 
avoid taking blood pressure measurement/injection of medication 
on this arm. 
 Evaluate patient for hypertension/hypotension. 
 Institute preoperative hemostatic aids (DDAVP (1-deamino-8-D-
arginine vasopressin, conjugated estrogen)) when appropriate. 
 Determine underlying cause of renal failure (underlying disease 
may affect provision of care). 
 Obtain routine annual dental radiographs to establish presence 
and follow manifestations of renal osteodystrophy. 
 Consider routine serology for HBV, HCV, and HIV antibody. 
 Consider antibiotic prophylaxis when appropriate. 
 Consider sedative premedication for patients with 
hypertension
61
. 
2. During treatment 
 Perform a thorough history and physical examination for 
presence of oral manifestations. 
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 Aggressively eliminate potential sources of infection/bacteremia. 
 Use adjunctive hemostatic aids during oral/periodontal surgical 
procedures. 
 Maintain patient in a comfortable uncramped position in the 
dental chair. 
 Allow patient to walk or stand intermittently during long 
procedures.
61
 
3. After treatment 
 Use postsurgical hemostatic agents. 
 Encourage meticulous home care. 
 Institute therapy for xerostomia when appropriate. 
 Consider use of postoperative antibiotics for traumatic 
procedures. 
 Avoid use of respiratory-depressant drugs in presence of severe 
anaemia. 
 Adjust dosages of postoperative medications according to extent 
of renal failure. 
 Ensure routine recall maintenance.61 
a) Renal transplant patient  
 These patients are immunosuppressed by medication. Maintenance 
of a proper oral health is especially important as oral infections in transplant 
patients can contribute to its morbidity or even rejection 
55
. They are usually 
receiving a treatment of corticosteroids, calcineurin inhibitors (tacrolimus) 
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and inhibitors of lymphocyte proliferation (azathioprine, mycophenolate 
mophetil)
49
. Long- standing treatment with high doses of corticosteroids 
produces an adrenal function suppression, which predisposes the patient to 
suffer an acute complication, adrenal crisis, when exposed to stressful 
situations like disease, infection, surgery. Furthermore, this chronic excess 
of corticosteroids can cause Cushing’s syndrome62. To minimize the risk of 
suffering an adrenal crisis in patients taking high doses of corticosteroids 
who are undergoing a surgical procedure, they should take a double dose of 
corticosteroids the day of the surgery. This supplement will not be necessary 
if the patient is being treated with low doses (less than 7.5 mg of 
prednisolone) or if the patient is undergoing a conservative treatment
52
. 
However, the risk of developing an adrenal crisis after oral surgery 
procedures under local anesthesia is very low and the majority of dental 
treatments can be carried out without prescribing a supplement of 
corticosteroids 
62
. 
REVIEW OF LITERATURE FOR ESRD AND NESRD IN 
DIABETES MELLITUS 
End Stage Renal Disease (ESRD) is the final syndrome for several 
primary renal diseases, and systemic diseases with renal involvement, 
causing kidney function loss. ESRD manifestations involve virtually every 
system, in a clinical condition known as uremic syndrome, characterized by 
a profound alteration of water, electrolyte, and acid-base homeostasis, as 
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well as retention of uremic toxins normally eliminated through urine, 
especially protein catabolism nitrogen waste products
63
. The condition is 
incompatible with life, unless the patient starts chronic dialysis treatment or 
kidney transplantation. 
ESRD incidence and prevalence are increasing, as shown in 
consecutive United States Renal Data System (USRDS) annual data reports. 
All age groups are affected, but ESRD is predominantly an adult disease. 
ESRD cause was Diabetes in 44.8% of incident USA cases in 2003. In that 
same report, chronic dialysis patient’s prevalence was 1,496 per million, and 
median age at dialysis start increased from 52.8 years in 1980, to 62.7 years 
in 2003, reflecting improved kidney disease medical care 
64
. 
An ESRD prevalence study on Instituto Mexicano del Seguro Social 
(IMSS)-affiliated adults (>18 yr), estimated 1.142 persons with creatinine 
clearance levels <15 ml/min per million adult affiliates 
65
. That level of renal 
function damage does already, or will soon, need dialysis treatment. Another 
study on IMSS affiliates found Diabetes Mellitus as the cause of ESRD in 
41.1% of incident cases. ESRD mortality is increasing in Mexico; being 
now 9th cause for women and 10th for men .Diabetes Mellitus is an 
important risk factor for ESRD
66
.  
Chi-yuan Hsu et al
67
 found The prevalence of chronic renal 
insufficiency among older adults was 10-fold that of younger individuals . 
However, younger individuals with chronic renal insufficiency were about 
3-fold more likely to progress to ESRD, presumably because of a decreased 
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risk for competing mortality Diabetic patients with chronic renal 
insufficiency were also about 3-fold more likely to progress to ESRD than 
Non-Diabetic patients with chronic renal insufficiency. For each 1000 cases 
of chronic renal insufficiency in 1991, 38 cases of ESRD developed among 
Diabetic patients in 1996 compared with 11 cases among Non-Diabetic 
patients 
In the REIN registry, among ESRD patients aged more than or 
equal to 45 years with associated diabetes, only 58.0% had Type 1 Diabetes 
in the year 2006 
68 
Zohreh Hajheydari and Atieh Makhlough
69
 found that the patients 
with chronic renal insufficiency were 43 (42.6%) women and 58 (57.4%) men 
with a mean age of 50.0 ± 12.3 years. The duration of hemodialysis was         
36.0 ± 11.0 months. Hair, mucous membrane, and nail problems were 
present in 37.6%, 23.8%, and 43.6% of the patients, respectively. There was 
a significant association of the number of cutaneous manifestations with the 
age of the patients (P = .001). Cutaneous and mucosal disorders are of the 
common problems in patients on long-term hemodialysis. The most 
common oral mucosal problem was furred tongue (7.9%). Of the nail 
disorders, nail bed paleness (16.8%) was the most common. 
 
Francois Madore et Al
70
 found variables of nutritional status 
(serum albumin and creatinine concentration), and the dose of dialysis (urea 
reduction ratio) were found to be significantly associated with hemoglobin 
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concentration (P < 0.001). Age, race, and gender were also found to be 
significantly associated with haemoglobin concentrations (P < 0.001). 
Gall et al
71
 conducted a prospective observational study involving 
176 patients with Type-2 Diabetes, and found that males had a 2.6 times 
greater risk of developing incipient or overt nephropathy. 
Choy BY et al
72
 found that for ESRD patients, the male/female ratio 
was reported to be about 1:1 for Diabetes Patients  
Olugbenga. E. Ayodele et al
73
 found that Smoking causes a 
substantial increase in the risk of both micro- and macrovascular diseases in 
Diabetes. Smoking is an independent risk factor for the development of 
Diabetic Nephropathy and is associated with an accelerated loss of renal 
function, an increased risk for ESRD, and decreased survival on 
commencement of dialysis. Loss of renal function is slower in those who 
stopped smoking. Cessation of smoking alone may reduce the risk of 
progression by 30% in patients with Type-2 Diabetes. 
Jorge l Gross et al
74
 found in 108 patients, that dietary protein 
restriction slowed the progression of Diabetic Nephropathy in patients with 
Type 1 Diabetes. More recently, a 4-year randomized controlled trial in 82 
patients with Type 1 Diabetes with progressive Diabetic Nephropathy 
showed that a moderately low–protein diet (0.9 g / kg / day) reduced the risk 
of end-stage renal disease or death by 76%. 
Thorman R, Neovius M and Hylander B
75
 conducted a study on 
101 patients and found 43 (42.6%) were women and 58 (57.4%) were men 
 Review of Literature 
  
 
 
33 
with a mean age of 50.0 ± 12.3 years. The most common causes of ESRD in 
the patients were hypertension in 30 (29.7%), Diabetes Mellitus in 12 
(11.9%), Diabetes Mellitus with hypertension in 14 (13.9%); and unknown 
causes in 14 (13.9%). oral fungal infection (OFI) was found in 32% of the 
ESRD patients and 11% of the controls (p=0.007). An extensive OFI, 
defined as frequent fungal hyphae formations in oral mucosal smear layers, 
was found in 3% of the PD and 17% of the HD patients. Oral lesions, 
defined as clinical signs associated with OFI such as erythematous oral 
stomatitis, membranous candidiasis or angular cheilitis, were found in 37% 
of the patients with OFI, while 5% of the patients without findings of fungal 
infection presented oral lesions associated with OFI (p=0.0002). 
Furthermore, patients with self-reported mouth dryness were three times 
more likely (p=0.02) to be diagnosed with OFI. Mucosal disorders were 
observed in 24% of the patients. Furred tongue, scrotal tongue, and 
deficiency glossitis were seen in 8%, 6%, and 3% of the patients, 
respectively, and the frequency of herpes simplex and gingivitis were 3% 
and 2%, respectively.  
Gábor L Kovács
76
 stated that the patients who have Type 1 Diabetes 
with nephropathy and hypertension, 50% will go on to develop end-stage 
renal disease within a decade. 80% of people who have Type 1 Diabetes and 
microalbuminuria will progress to overt nephropathy (i.e. proteinuria 
characterized by > 300 mg albumin excreted daily), whereas only 20-40% of 
those with Type 2 Diabetes over a period of 15 years will progress. 
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Britt B Newsome et al
77 
conducted a study on 87,094 patients, and 
found there were statistically significant interactions between creatinine 
change and race (P=.04), age (P<001), history of hypertension (P=.01), and 
history of Diabetes Mellitus (P<.001) with respect to the outcome of ESRD, 
Ritz E, Bergis K, Strojek K and Keller C
78
 found that Diabetic 
Nephropathy in patients with type II diabetes has become the most frequent 
cause of End stage Renal Failure in Germany. Preventive measures, i. e. 
near normal glycemia and particularly antihypertensive treatment, have been 
proven to interfere with progression of renal failure in diabetic nephropathy. 
Early recognition is possible by testing for urinary albumin 
(microalbuminuria). In patients with Diabetic Nephropathy, blood pressure 
should be lowered to values well within the range of normotension by 
dietary salt restriction and antihypertensive drug therapy 
Barry i. Freedman et al
79
 conducted a study in which the family 
histories were obtained from 4365 dialysis patients, 856 (20%) reported 
having a family history of ESRD 
Udayakumar P et al
80
 conducted a study on One hundred patients 
with CRF on hemodialysis and found Oral changes included macroglossia 
with teeth markings (35%), xerostomia (31%), ulcerative stomatitis (29%), 
angular cheilitis (12%) and uremic breath (8%). Some rare manifestations of 
CRF like uremic frost, gynecomastia and pseudo-Kaposi’s sarcoma were 
also observed. Ulcerative stomatitis seen in 29% is reported to occur in 
patients with blood urea level more than 150mg/ml . 
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Shu-Fen Chuang et al
81
 conducted a study in which they found that 
the incidence of uremic odour in Diabetic groups (27.9%). Uremic odour is 
associated with the accumulation of urea in the saliva. Higher incidence of 
uremic odour may correlate with higher urea in saliva of CRF patients.  
Incidence of mucosal petechia / ecchymosis was 20.9% in the diabetic.  
Patients with poor glycemic control also presented with a higher incidence 
of tongue/mucosa pain and tongue coating. Additionally, oral ulceration was 
rare. The mucosal petechia/ecchymosis is associated with the anticoagulants 
in hemodialysis sessions. Low incidence of these soft tissue lesions may 
reflect well controlled status of anticoagulants in these patients 
P. Mosannen Mozaffari et al
82 
stated that, one of the early 
symptoms may be a bad metallic taste and unpleasant odour in the mouth 
particularly in the morning. This uremic fetor, an ammoniacal odour is a 
typical sign of all uremic patients which is caused by the high concentration 
of urea in the saliva and its subsequent breakdown to ammonia. Salivary 
urea level correlates well with the BUN so that saliva can be used as a non 
invasive diagnostic tool. An acute rise in BUN (>150 mg/dl) may result in 
uremic stomatitis which disappear 2 to 3 weeks after medical intervention 
and decreasing BUN. Four of 300 patients with uremia were observed to 
have probable uremic stomatitis in the 1930s, while in 1964 another 4 
affected patients were reported from a group of 262 patients with renal 
disease. 
 Review of Literature 
  
 
 
36 
 Uremic stomatitis is considered as a kind of chemical burn. The red 
burning mucosa is covered with gray exudates and would be ulcerative later. 
Four types of uremic stomatitis have been described: erythemopultaceous, 
ulcerative, hemorrhagic and hyperkeratotic. This lesion is painful and 
appears on the ventral surface of tongue and anterior mucosal surfaces. The 
most prevalent mucosal finding is pale mucosa as a result of 
normochromic/normocytic anaemia caused by decreasing of erythropoietin 
but increasing hemolysis due to dialysis procedure and uremic toxins. 
Lichenoid reaction (drug induced) and pyogenic granuloma are frequently 
observed in CRF patients. Caroten –like material deposition gives oral 
mucosa an orange-red color is seen. Gingival bleeding, petechia and 
ecchymosis develop in labial and buccal mucosa, soft palate and tongue 
borders as a result of qualitative and to a lesser degree, quantitative platelet 
defects. Anticoagulants used for hemodialysis can be a predisposing factor. 
A M El Nahas et al
83
 found that the ratio of plasma urea to 
creatinine concentration accurately reflected the dietary protein intake, it 
rose to 110 during the high protein diet and subsequently fell to 40 during 
the low protein diet (p <0 025). 
Sanjay Kumar Agarwal et al
51
, stated that A serum creatinine 
persistently >1.8mg% for 8–12 weeks in the absence of any reversible factor 
was the criterion to diagnose Chronic Renal Failure. 
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Agarwal et al
84
 screened.4900 persons in urban communities of 
Delhi and found a .79% point prevalence of persons with serum creatinine 
more than1.8 mg/dL. 
Robert N. Foley et al
85
 found that the initial laboratory findings in 
patients starting renal replacement therapy (RRT) have also changed 
considerably from year to year. On  comparing 1996 and 2005, initial 
hemoglobin levels rose from 9.3 to 10.2 g/dl, blood urea nitrogen fell from 
94.0 to 83.3 mg/dl, serum creatinine fell from 8.5 to 6.8 mg/dl, and 
estimated GFR rose from 7.7 to 10.1 ml/min per 1.73 m
2
. 
De La Rosa García E et al
66
 evaluated 229 individuals, Two adult 
groups were studied: Group A: ESRD DM on dialysis, and group B: non-
ESRD DM (serum creatinine <2.0 mg/dl). Group A 99, and Group B 130 
pts. Signs and symptoms prevalence was higher in group A:  uremic breath 
(48.5%), unpleasant taste (45.5%) and xerostomia (44.4%) being the most 
frequent ones. Oral Lesions were also more prevalent in group A. The most 
frequent Oral Lesions were dry, fissured lips (28.3%), saburral tongue 
(18.2%) and candidiasis (17.2%). No difference was found in candidiasis 
prevalence between groups. Candidiasis was found associated to xerostomia 
and smooth tongue only in group A. The high prevalence of uremic fetor, 
xerostomia, saburral tongue and candidiasis in group A, could be tried as 
warning signs on the possibility of non diagnosed advanced renal disease in 
other diabetic patients 
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Sowell SB
86
, Carl W and Wood RH
87
, Hovinga J et al
88
 found 
Uremic stomatitis is often a clinical finding in cases of advanced disease. 
There are two forms of this stomatitis; often, they correspond with an acute 
rise in BUN levels. The erythemopultaceous form is characterized by red, 
burning mucosa covered with a gray exudate and pseudomembrane; the 
ulcerative form is characterized by frank ulceration with redness and a 
pultaceous covering. The exact etiology of uremic stomatitis remains 
unknown, but it is suspected to be a chemical like burn or a loss of the 
tissue's resistance to normal and/or traumatic influences. These lesions are 
commonly painful and most often appear on the ventral tongue and anterior 
mucosal surfaces. These lesions usually heal spontaneously, with resolution 
of the underlying uremia and lowering of BUN levels.
 
Vesterinen M
 
et al
89
 conducted a cross-sectional study in the 
Helsinki University Central Hospital, Finland, on 148 patients with different 
kinds of kidney disease at predialysis state. Data from medical records, 
clinical oral examination, saliva, and mucosal yeast counts were analyzed 
and compared between the disease groups. Of the patients, 53 (36%) had 
Diabetic Nephropathy (29 patients with type 1, 24 patients with Type 2 
Diabetes). Compared with other CKD patients, diabetic patients had poor 
glycemic control as expected (mean HbA1C) 8.0% vs 5.9%, (p<0.01). 
Diabetic patients also had more dental caries (mean number of carious teeth 
5.1 vs 3.1, p<0.01) and lower salivary flow rates than other CKD patients 
(stimulated salivary flow 1.2 ml/min vs 1.6 ml/min, p<0.05). No difference 
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between groups was observed in periodontal health and yeast counts. 
Diabetic Nephropathy patients indeed had worse dental health in 
comparison to CKD group. Diabetic Nephropathy did not seem to affect 
periodontal health more severely than the other kidney diseases 
Gavaldá et al
90
 examined the oral mucosa of individuals with 
chronic renal failure and noted several mucosal lesions, uremic stomatitis 
and Candida infections in 37% of these patients.  
Thorman R et al
75
 evaluated 93 ESRD patients and 45 age- and 
gender-matched controls. In total, 34 patients were treated with peritoneal 
dialysis (PD) and 59 with hemodialysis (HD). OFI was found in 32% of the 
ESRD patients and 11% of the controls (p=0.007). An extensive oral fungal 
infection (OFI), defined as frequent fungal hyphae formations 
in oral mucosal smear layers, was found in 3% of the PD and 17% of the 
HD patients. Oral lesions, defined as clinical signs associated with OFI such 
as erythematous oral stomatitis, membranous candidiasis or angular 
cheilitis, were found in 37% of the patients with OFI, while 5% of the 
patients without findings of fungal infection presented oral lesions 
associated with OFI. Furthermore, patients with self-reported mouth dryness 
were three times more likely to be diagnosed with OFI. 
De la Rosa-García E et al
91
 performed a study in 90 patients of 
which Fifty (55.6%) men and forty (44.4%) women were studied. Sixty 
percent of the patients had at least one OL. Oral candidiasis (OC) was found 
in 18.7%; 13% had lesions clinically compatible with hairy leukoplakia 
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(CHL). An association was found between OC and CHL (P<0.05). Saburral 
tongue (ST) was found in 22% of the patients and gingival hyperplasia (GH) 
in 49%. 
Safia A. Al-Attas et al
92
 conducted a study on 150 Diabetics. They 
found that the number of patients with candidal carriage from the oral cavity 
was higher in patients with Type 1 Diabetes than in type 2 (P=.003). 
E. de la Rosa García et al
93
 conducted a study on ESRD DM and 
DM groups, in that order, consisting of 103 and 130 patients respectively. 
No differences were found in age (57.9 ± 11.4 vs 58.5 ± 11.5 years, p = 
0.716), sex distribution, or schooling. Age at diagnosis of Type 2 Diabetes 
was    38.5 ± 14.0 vs 47.8 ± 12.1 years (p < 0.001). In ESRD DM patients, 
the median known duration of diabetes before dialysis was 17 years (1-39), 
and the median time on dialysis 7 months (1-88). Fourteen (13.6%) ESRD 
DM and 29 (22.3%) DM patients reported current or prior smoking (p = 
0.088); 45.6% and 26.9% (p = 0.003) reported unpleasant taste, and dry 
mouth (p = 0.011). 
REVIEW OF LITERATURE FOR DRUGS CAUSING 
ESRD AND NESRD IN DIABETES MELLITUS 
Abe M et al
94 
stated that Conventional oral hypoglycemic agents, 
such as sulfonylurea (SU), are not suitable due to the risk of prolonged 
hypoglycemia; furthermore, metformin is contraindicated for moderate to 
advanced CKD. Therefore, in order to achieve good glycemic control, 
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insulin injection therapy remains the mainstay of treatment 
in diabetic patients with moderate to advanced CKD, particularly in those 
receiving dialysis therapies. However, some agents have been used even in 
patients with CKD. Repaglinide and mitiglinide are rapid- and short-acting 
insulinotropic SU receptor ligands. They are rarely accompanied by 
hypoglycemia, and are attractive therapeutic options even in the dialysis 
population. In addition, alpha-glucosidase inhibitors are rarely accompanied 
by hypoglycemia and are administered without dose adjustments in dialysis 
patients. However, the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative guidelines recommended that alpha-glucosidase 
inhibitors should be avoided in patients with advanced stage CKD and on 
dialysis. Furthermore, mitiglinide is not currently used in the US. Thus, 
recommended oral antidiabetic agents differ between countries. Moreover, 
dipeptidyl peptidase-4 inhibitors and incretin mimetics are new 
antihyperglycemic agents, which may be used more frequently in the future 
in patients with Type 2 Diabetes and CKD. Here, we describe the 
pharmacokinetics, metabolism, clinical efficacy, and safety 
of oral Antidiabetic agents for patients with CKD, including those receiving 
dialysis 
Jean-François Yale
95 
found that in chronic renal failure, the oral 
agents that can be used therefore include the insulin secretagogues 
repaglinide and nateglinide and the thiazolidinediones (rosiglitazone and 
pioglitazone) with caution. Insulin also can be used safely in renal failure. 
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Jorge l Gross et al
74
 stated that Metformin should not be used when 
serum creatinine is >1.5 mg/dl in men and >1.4 mg/dl in women due to the 
increased risk of lactic acidosis. Sulfonylureas and their metabolites, except 
glimepiride, are eliminated via renal excretion and should not be used in 
patients with decreased renal function Thus; most type 2 diabetic patients 
with Diabetic Nephropathy should be treated with insulin. 
M. Greenwood et al
96
 stated that Insulin given by injection may 
cause pain and swelling of the salivary glands. The oral hypoglycaemic 
metformin may produce a metallic taste. Sulphonylurea hypoglycaemics 
such as gliclazide and glibenclamide have been implicated in causing oral 
lichenoid eruptions, erythema multiforme and orofacial neuropathy such as 
burning tongue. 
Janelle C Nisbet et al
97
 found that life-threatening lactic acidosis 
can occur, caused by accumulation of metformin, and that risk factors for 
this include renal impairment, old age and doses over 2 g per day. The 
estimated prevalence of life-threatening lactic acidosis is one to five cases 
per 1,00,000 with mortality in reported cases up to 50%. 
Devasmita Choudhury et al
98
 suggested the Use of metformin and 
the first-generation sulfonylurea agents chlorpropamide, tolbutamide and 
tolazamide, as well as the α-glucosidase inhibitors acarbose and miglitol, 
should be avoided in patients with advanced CKD or ESRD, in light of their 
association with metabolic acidosis and prolonged hypoglycemia. 
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STUDY TOPIC 
 To assess oral signs, symptoms and oral lesions type and 
prevalence, in diabetic patients with End Stage Renal Disease (ESRD-DM) 
and compare them with analogous findings in Non-End Stage Renal Disease 
(NON-ESRDDM) group. 
STUDY DESIGN 
The present study is a comparative Study. 
STUDY DURATION 
This study was conducted between June 2010 to May 2011 in the 
department of Oral Medicine and Radiology of Ragas Dental College and 
Hospital, and Voluntary Health Services, Adyar, Chennai. 
STUDY POPULATION 
The study population includes patients reporting to Ragas Dental 
College & Hospital, Chennai, and Voluntary Health Services, Adyar, 
Chennai, who were diagnosed as Diabetic patients with End Stage Renal 
Disease (ESRD-DM) and with Non-End Stage Renal Disease (NESRD-DM) 
group. 
Sample size – 200 Patients  
1. 100 Diabetic patients with End Stage Renal Disease 
2. 100 Diabetic patients  with Non-End Stage Renal Disease 
OBTAINING APPROVAL FROM THE AUTHORITIES 
Permission from the ethical committee of the Ragas Dental College 
& Hospital, and Voluntary Health Services, Adyar, Chennai was obtained 
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before starting the study for interrogating and examining the patients. All 
patients participating in the study had to give written informed consent for 
participation in English or Tamil accordingly. 
INSTRUMENTS USED 
1. Dental chair with halogen lamp 
2. Disposable latex gloves 
3. Mouth mask 
4. Plain mouth mirror 
5. Dental probe 
6. Mettalic scale 
7. 2 X 2 gauze 
8. Torch Light 
METHODOLOGY 
The 200 Diabetic patients, who are diagnosed as having Non-End 
Stage Renal Disease and End Stage Renal Disease undergoing dialysis will 
be taken up for the study. These patients will undergo general clinical 
examination to exclude HIV. Patients are examined for the presence of intra 
oral manifestations of Diabetic patients with End Stage Renal Disease 
(ESRD-DM) and with Non-End Stage Renal Disease (NESRD-DM) like 
saburral tongue, smooth tongue, burning tongue, candidiasis, dry and 
fissured lips, petechiae or ecchymoses, ulcerative or uremic stomatitis, 
herpes simplex, angular cheilitis, uremic fetor, xerostomia, pale mucosa. 
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END STAGE RENAL DISEASE IN DIABETIC PATIENTS 
INCLUSION CRITERIA 
1. Both sexes 
2. Patient in age group of 12 years and above 
3. Diabetic patients with End Stage Renal Disease on Dialysis 
EXCLUSION CRITERIA 
1. Patients with HIV infection 
NON-END STAGE RENAL DISEASE IN DIABETIC PATIENTS 
INCLUSION CRITERIA 
1. Both sexes 
2. Patient in age group of 12 years and above 
3. Diabetic patients with Non-End Stage Renal Disease, Serum 
Creatinine is less than or equal to 2.0mg/dl 
EXCLUSION CRITERIA 
1. Patients with HIV infection 
2. Patients with Serum Creatinine Level >2.0mg/dl 
Data was collected from subjects fulfilling the above said criteria.  
CLINICAL CRITERIA FOR DIAGNOSIS 
SABURRAL TONGUE 
Yellowish-white plaque on tongue dorsum, which could not be 
scraped-off by a blunt instrument. Slightly elongated filiform papillae and 
bacterial accumulation were found
66
.  
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FISSURED TONGUE 
It is characterized by grooves that vary in depth and are noted along 
the dorsal and lateral aspects of the tongue
99
. 
CANDIDIASIS 
It is the most common fungal infection. It has various forms in 
which pseudo-membranous type has loosely attached membrane which 
when removed leaves a raw bleeding area; erythematous type is a successor 
to pseudo-membranous candidiasis which is red with diffuse borders and 
plaque-like or nodular  candidiasis appears as a thick white plaque
100
.  
DRY AND FISSURED LIPS 
The lips are dry, peeling or chapped. Breaks may appear on the 
surface, and the lips may become painful and may bleed
100
. 
PETECHIAE OR ECCHYMOSES 
Purpura is the appearance of red or purple discolorations on 
the skin that do not blanch on applying pressure. They are caused 
by bleeding underneath the skin / Mucosa.  
Purpura measure 0.3–1 cm (3–10 mm), whereas petechiae measure 
less than 3 mm, and ecchymoses greater than 1 cm. 
Petechia refers to one of the three major classes 
of purpuric skin/mucus membrane conditions. Purpuric eruptions are 
classified by size into three broad categories. Petechiae are generally used to 
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refer to the smallest of the three classes of purpuric skin/mucous membrane 
eruptions, those that measure less than 3 mm. 
Petechiae may be a sign of thrombocytopenia (low platelet counts) 
when platelet function is inhibited (e.g., as a side effect of medications or 
during certain infections), or in clotting factor deficiencies. They may also 
occur when excessive pressure is applied to tissue (e.g., when a tourniquet is 
applied to an extremity or with excessive coughing or vomiting). 
By definition, ecchymoses are 1 to 2 cm in size or larger, and are therefore 
larger than petechiae (1–2 mm). A subcutaneous purpura larger than 1 
centimeter
101 
SMOOTH TONGUE 
Smooth tongue is a condition characterized by a smooth glossy 
tongue that is often tender /painful.  The atrophy of papillae, resulting in a 
smooth tongue. The tongue may be pale or erythematous and may appear 
small or enlarged
102
 
BURNING TONGUE 
Burning Tongue is a condition characterized by a burning or tingling 
sensation on the lips, tongue, or entire mouth. This condition appears more 
often in women, specifically women after menopause, than men. Pain 
typically is low or nonexistent in the morning and builds up over the course 
of the day
102 
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ULCERATIVE OR UREMIC STOMATITIS 
An acute rise in BUN (>150 mg/dl) may result in uremic stomatitis 
which disappear 2 to 3 weeks after medical intervention and decreasing 
BUN.  
Uremic stomatitis is considered as a kind of chemical burn. The red 
burning mucosa is covered with gray exudates and would be ulcerative later. 
Four types of uremic stomatitis have been described: erythemopultaceous, 
ulcerative, hemorrhagic and hyperkeratotic. 
The erythemopultaceous form is characterized by red, burning 
mucosa covered with a gray exudates and pseudomembrane.  
The ulcerative form is characterized by frank ulceration with redness and a 
pultaceous covering.  
Clinically, adherent white lesions arise on the dorsal, ventral, and 
lateral parts of the tongue, as well as in the buccal, labial, or retro-molar 
areas.4 However, some patients may have an exudate from the oral mucosa, 
together with ulcerative lesions of the skin
82
. 
HERPES LABIALIS 
The presence of clusters of vesicles which ruptures  to form round, 
symmetric, shallow ulcers which coalesce to form larger ulcer with 
scalloped borders and marked surrounding erythema along the vermilion 
border of the lips
102
. 
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ANGULAR CHEILITIS 
Angular cheilitis is an inflammatory lesion at the labial commissure, 
or corner of the mouth, and often occurs bilaterally. The condition manifests 
as deep cracks or splits. In severe cases, the splits can bleed when the mouth 
is opened and shallow ulcers or a crust may form. 
It is infected fissures of the commissures of the mouth  which may 
ulcerate or develop super added candidal infection surrounded by erythema 
caused due to nutritional deficiencies or decreased vertical dimension of the 
complete denture
102 
UREMIC FETOR 
Uremic fetor was identified when the patient had a urine-odor breath 
in persons with uremia
66
. The odor occurs from the smell of ammonia, 
which is created in the saliva as a breakdown product of urea. Uremic fetor 
is usually associated with an unpleasant metallic taste (dysgeusia)
81
. 
XEROSTOMIA 
A diagnosis of xerostomia was made when a dry or sticky mucosa 
was found, and when the patient reported a dry mouth; saliva flow was not 
measured
66
  
PALE MUCOSA 
Pallor is condition caused by a reduced amount 
of oxyhaemoglobin in the skin or mucous membrane, a pale colour which 
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can be caused by illness, emotional shock or stress, stimulant use, lack of 
exposure to sunlight, anaemia or genetics. 
It can develop suddenly or gradually, depending on the cause. It is 
not usually clinically significant unless it is accompanied by a general pallor 
(paleness of the lips, tongue, palms, mouth and other regions with mucous 
membranes)
102
. 
LICHEN PLANUS 
Oral lichen planus is a mucocutaneous disease that affects skin, 
mucosa or both. It has both red and white components. It is usually bilateral 
with white striations called as Wickham’s striae and commonly occurs on 
the buccal mucosa, tongue and gingiva. On palpation, the surface texture 
rough with loss of suppleness
102
. 
INVESTIGATIONS REQUIRED 
Blood Sample Collection 
Blood samples are taken from the vein in the antecubital fossa. The 
tourniquet is set around the upper arm of the subject, search for the proper 
vein by inspecting and palpating and then sterilize the injection site. The 
vein can be anchored by placing the thumb about two centimeters below the 
vein and pulling gently to make the skin a little taut. After that, the needle, 
beveled upward, should be pushed smoothly and quickly into the vein, to 
minimize the possibility of hemolysis as a result of vascular damage. 
Immediately after the insertion, the tourniquet should be released to 
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minimize the effect of hemoconcentration. 5 ml of venous blood was drawn 
and the serum was separated by centrifugation, supernatant was aspirated. 
The samples were centrifuged no later than 30 minutes after the sample was 
drawn. EDTA and Sodium Fluoride were added to prevent the coagulation 
of blood. All samples were centrifuged at 3000 rpm for 10 min to remove 
particulate materials. This freshly obtained serum was used immediately for 
biochemical analysis 
Biochemical Analysis 
Estimation of Creatinine in Serum 
Modified Jaffe’s Kinetic Method103 was used to estimate the levels 
of Creatinine in serum.
 
Reagents 
1. L1 : Picric Acid Reagent  
2. L2 : Buffer Reagent  
3. S : Creatinine Standard (2 mg/dl) 
Procedure 
100µL of the freshly obtained serum will be mixed with 0.1 mL of 
creatinine Standard (S), 0.5ml of picric acid reagent (L1) and buffer reagent 
(L2) each in test tube. Mix well and and the supernatant is read at 520 nm in 
a spectrophotometer (photometer 5010 V5+, ROBERT RIELE KG, 
BERLIN). The levels of creatinine in serum is expressed in term of mg/Dl 
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Estimation of Urea Level in Serum 
Modified Berthelot Method
104
 was used to estimate the levels of urea 
level in serum.
 
Reagents 
1. L1 : COLOR Reagent  
2. L2 : Enzyme Reagent  
3. L3 : BASE Reagent 
Procedure 
10µL of the freshly obtained serum will be mixed with 0.5 ml of 
COLOR Reagent (L1), Add 0.5 ml of ENZYME Reagent (L2) mix gently, 
and incubate at 37°C for five minutes. Add 2.0 ml of BASE Reagent (L3), 
mix and incubate at 37°C for 5 minutes. Measure the absorbance of the mix 
at 630 nm by photometer (photometer 5010 V5+, ROBERT RIELE KG, 
BERLIN). The levels of Urea in serum is expressed in term of mg/dL 
Estimation of Fasting Blood Glucose Level in Serum 
GOD-POD Method
105
 was used to estimate the levels of Fasting 
blood glucose in serum. 
Reagents 
1. L1 : Glucose standard  Reagent  
Procedure 
10µL of the freshly obtained serum will be mixed with 1000µL of 
Glucose standard Reagent (L1) in the test tube. Mix well & incubate for 15 
min at room temperature or 7 min at 37 
0
C. Measure the absorbance of the 
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mix at 505 nm by photometer (photometer 5010 V5+, ROBERT RIELE 
KG, BERLIN) at 630nm. The levels of Fasting blood glucose in serum is 
expressed in term of mg/Dl 
Estimation of Hemoglobin Level in Blood 
The Cyanmethemoglobin Method
106
 was used to estimate the levels 
of hemoglobin in blood. 
Reagents 
1. L1 : cyanmethemoglobin reagent (Drabkin's solution) 
Procedure 
Pipette 5 ml of cyanmethemoglobin reagent into each tube.  Add 20 l of the 
blood sample into test tube. Allow tube to stand for 10 minutes. Read Absorbance 
(A) in the spectrophotometer at 540 nm, by photometer (photometer 5010 V5+, 
ROBERT RIELE KG, BERLIN). The levels of hemoglobin level in Blood is 
expressed in term of g/dL 
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STATISTICAL ANALYSIS 
All the data were entered in Microsoft excel sheets. Statistical 
analysis was done   using SPSS software SYSTAT version 7.0 
Mean: defined as sum of values (X) divided by the number of values (N) 
and denoted by                            
P > 0.05 =  Difference is not significant 
 
P ≤ 0.05 = Difference is significant (S) 
P ≤ 0.01 = Difference is highly significant (S) 
P ≤ 0.001 = Difference is very highly significant (HS) 
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RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, East Coast Road, Uthandi, Chennai - 600119 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
CASE SHEET PROFORMA 
                                                                                      Date: 
Name: 
Age: 
Sex: 
Occupation: 
Income: 
Address: 
 
Phone number: 
Tobacco related habits: 
Dietary habits: 
Medical history: 
1. Systemic disease: 
2. Diabetes mellitus: 
a) Duration  of diabetes: 
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b) Family history: 
c) Medication: 
Investigations: 
Serum creatinine level: 
Blood glucose level:   fasting sugar:                      
Serum urea level: 
Oral lesion present: 
 Saburral tongue : 
 Candidiasis: 
 Dry and fissured lips: 
 Petechiae or ecchymoses: 
 Smooth tongue: 
 Burning tongue: 
 Ulcerative or uremic stomatitis: 
 Herpes simplex: 
 Angular cheilitis: 
 Uremic fetor: 
 Xerostomia: 
 Pale mucosa:  
 Other lesions: 
 Figures 
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Figure 1: Armamentarium for Clinical Examination 
 
 
 
 
Figure 2:  Armamentarium for Blood Investigation 
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Figure 3: Aramamentarium for Estimation of Serum 
Creatinine, Blood Glucose Level, Blood Urea Level, 
Hemoglobin Level 
 
 
 
 
Figure 4 :Laboratory Centrifuge Machine 
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Figure 5: Spectrophotometer for Estimation of Circulating 
Immune Complex 
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Figure 6 : Hemodialysis Procedure 
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Figure 7 : Saburral Tongue 
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Figure 8 : Fissured Tongue 
 
 
 
 
 
 Figures 
 
 
63 
 
 
 
Figure 9 : Oral Candidiasis 
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Figure 10 : Dry and Fissured Lips 
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Figure 11: Petechiae or Ecchymoses 
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Figure 12: Smooth Tongue 
 
 
 
   
 
 
Figure 13: Ulcerative or Uremic Stomatitis 
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    Figure 14: Herpes Simplex 
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Figure 15: Angular Cheilitis 
 
 
     
 
 
 
 
 
 
Figure 16: Xerostomia 
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Figure 17: Pale Mucosa 
 
 
Figure 18: Oral Lichen Planus 
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The present study is a Comparative study which was conducted in 
the Department of Oral Medicine and Radiology of Ragas Dental College 
and Hospital, Uthandi, Chennai and Voluntary Health Services, Adyar, 
Chennai. It was devised to compare the oral signs, symptoms and oral 
lesions type and prevalence in Diabetic patients with End Stage Renal 
Disease (ESRD-DM) and with Non-End Stage Renal Disease (NESRD-DM) 
group. The study was conducted between June 2010-March 2011 on a total 
of 200 diabetic patients, who are diagnosed as having End Stage Renal 
Disease-undergoing dialysis and Non-End Stage Renal Disease. The data 
obtained from the study were statistically analyzed.  The results extracted 
are compared with various variables included in the study and are presented 
here. 
Table 1: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Sex 
 The study group consists of 200 subjects, 79 patients were male and 
121 patients were female. Out of the 100 ESRD patients, 41 patients 
(51.90%) are found to be male and 59 patients (48.80%) are found to be 
female .Among the 100 NESRD patients, 38 patients (48.10%) are male and 
62 patients (51.20%) were female. 
 The sex wise distribution of subjects were found to be statistically 
non significant, which means that both ESRD and NESRD among Diabetes 
Mellitus patients were not similar with respect to sex in distribution with     
P value is ≥ 0.664 
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TABLE 2: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to age  
The age of the subjects included in the study ranges between 1-100 
years. So the subjects were divided into five age groups which are as 
follows: 12-40 years, 41-60 years, 61-80 years and 81-100 years. Among 
200 patients,  72 were in age group of 12-40 years, 101 patients were in age 
group of 41-60 years, 24 patients were in age group of 61-80 years, and 3 
patients were in the age group of 81-100 years. Among the 100 patients in 
ESRD- diabetes mellitus patients, 22 (30.56%) were between 12-40yrs, 59 
(58.41%) were between 40- 60 yrs, 17 (70.83%) were between 60-80 yrs, 2 
(66.67%) were between 80-100 yrs, the mean age group affected by ESRD 
is 50.77. Among the 100 patients in NESRD- diabetes mellitus patients, 50 
(69.44%) were between 12- 40 yrs, 42 (41.59%) were between 40-60 yrs, 7 
(29.17%) were between 60-80 yrs, 1 (33.33%) were between 80-100 yrs, the 
mean age group affected by NESRD is 40.82. 
The age wise distribution of subjects were found to be statistically 
significant, which means that there exists correlation among the 2 groups 
with respect to age in distribution with P value ≤ 0.000.  
TABLE 3: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to habits. 
Among the 200 patients, 141 patients did not have any habits, 35 patients 
have smoking habits, and 24 patients have tobacco related habits. Among 
100 ESRD patients, 60 (42.60%) patients did not have any habits,              
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22 (62.90%) patients have smoking habits, and 18 (75%) patients have 
tobacco related habits. Among 100 NESRD patients, 81 (57.40%) patients 
did not have any habits, 13 (37.10%) patients have smoking habits, and 6 
(25%) patients have tobacco related habits 
The distribution of subjects based on habits were found to be statistically 
significant, which means that there exists correlation among the 2 groups 
with respect to habit in distribution with P value ≤ 0.003 
TABLE 4: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to diet 
Among the 200 patients, 106 patients were on renal diet, 91 patients 
were on vegetarian diet and 3 patients were on Non vegetarian diet. Among 
100 ESRD patients, 29 patients (27.4%) were on renal diet, 68 patients 
(74.70%) were on vegetarian diet and 3 (100%) patients were on Non 
vegetarian diet. Among 100 NESRD patients, 77 patients (72.6%) were on 
renal diet, 23 patients (25.30%) were on vegetarian diet and 0 (0%) patients 
were on Non vegetarian diet 
The distribution of subjects based on diet were found to be 
statistically significant, which means that there exists correlation among 
the 2 groups with respect to habit in distribution with P value ≤ 0.000 
TABLE 5: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Type of Diabetes Mellitus 
Among the 200 patients, 39 patients were IDDM (Insulin– 
Dependent Diabetes Mellitus) and 161 patients were NIDDM (Non Insulin – 
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Dependent Diabetes Mellitus). Among 100 ESRD patients, 17 (43.6%) were 
IDDM (Insulin – Dependent Diabetes Mellitus) patients and 83 (51.60%) 
were NIDDM (Non Insulin – Dependant Diabetes Mellitus) patients. 
Among 100 NESRD patients, 22 (56.4%) were IDDM (Insulin – Dependant 
Diabetes Mellitus) patients and 78 (48.4%) were NIDDM (Non Insulin – 
Dependant Diabetes Mellitus) patients 
The distribution of subjects based on Type of Diabetes Mellitus were 
found to be statistically not significant, which means that there exists no 
correlation among the 2 groups with respect to Type of Diabetes Mellitus in 
distribution with P value ≥ 0.372 
TABLE 6: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Duration of Diabetes Mellitus 
The Duration of Diabetes Mellitus of the subjects included in the 
study ranges between 1yr - 80 years. So the subjects were divided into four 
groups which are as follows: 1-12 yrs, 13-40 years, 41-60 years, and 61-80 
years. Among the 200 patients, 140 were between 1-12 yrs, 59 were 
between 13-40yrs, 1 (100%) were between 41- 60 yrs, 0 (0%) were between 
61-80 yrs. Among the 100 patients in ESRD- diabetes mellitus patients, 54 
(38.58%) were between 1-12 yrs, 45 (76.28%) were between 13-40yrs, 1 
(100%) were between 41- 60 yrs, 0 (0%) were between 61-80 yrs. The mean 
duration of Diabetes Mellitus age group affected by ESRD is 14.39yrs. 
Among the 100 patients in NESRD- Diabetes Mellitus patients, 86 (61.42%) 
were between 1-12 yrs, 14 (23.72%) were between 13-40 yrs, 0 (0%) were 
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between 41-60 yrs, 0 (0%) were between 61-80 yrs, the mean duration of 
Diabetes Mellitus group affected by NESRD is 5.82yrs. 
The distribution of subjects based on duration of Diabetes Mellitus 
was found to be statistically very highly significant, which means that 
there exists correlation among the 2 groups with respect to age in 
distribution with P value ≤ 0.000. 
TABLE 7: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to family history of Diabetes Mellitus 
Among the 200 patients, 46 patients had family history of Diabetes 
Mellitus and 154 patients did not have any family history of Diabetes 
Mellitus. Among 100 ESRD patients, 24 (52.2%) had family history of 
Diabetes Mellitus and 76 (49.40%) patients did not have any family history 
of Diabetes Mellitus. Among 100 NESRD patients, 22 (47.8%) had family 
history of Diabetes Mellitus and 78 (50.60%) patients did not have any 
family history of Diabetes Mellitus 
The distribution of subjects based on family history of Diabetes 
Mellitus were found to be statistically not significant, which means that 
there exists no correlation among the 2 groups with respect to family history 
of Diabetes Mellitus in distribution with P value ≥ 0.737 
TABLE 8: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to fasting blood sugar level 
The fasting blood sugar level of the subjects included in the study 
ranges between 0-200 mg/dl. So the subjects were divided into three groups 
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which are as follows: less than 120 mg/dl, 120-200 mg/dl, and more than 
200 mg/dl. Among the 200 patients, 71 were found to be less than 120 
mg/dl, 79 were between 120-200 mg/dl, 50 were more than 200 mg/dl. 
Among the 100 patients in ESRD- Diabetes Mellitus patients, 30 (42.25%) 
were found to be less than 120 mg/dl, 42 (53.17%) were between 120-200 
mg/dl, 28 (56%) were more than 200 mg/dl. the mean value for the fasting 
blood sugar level in ESRD patients is 161.63mg/dl. Among the 100 patients 
in NESRD- diabetes mellitus patients, 41 (57.75%) were found to be less 
than 120 mg/dl, 37 (46.83%) were between 120-200 mg/dl, 22 (44%) were 
more than 200 mg/dl. The mean value for the fasting blood sugar level in 
NESRD patients is 153.18mg/dl 
The distribution of subjects based on fasting blood sugar level were 
found to be statistically not significant, which means that there exists no 
correlation among the 2 groups with respect to fasting blood sugar level in 
distribution with P value  ≥ 0.330 
TABLE 9: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Hypertension 
Among the 200 patients, 40 patients were hypertensive and 160 
patients were normotensive. Among 100 ESRD patients, 26 (65%) were 
hypertensive patients and 74 (46.30%) were normotensive. Among 100 
NESRD patients, 14 (35%) were hypertensive patients and 86 (53.70%) 
were normotensive.  
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The distribution of subjects based on Hypertension were found to be 
statistically significant, which means that there exists correlation among 
the 2 groups with respect to habit in distribution with P value ≥ 0.034 
TABLE 10: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to hemoglobin level 
The hemoglobin level of the subjects included in the study ranges 
between 0-20 mg/dl. So the subjects were divided into three groups which 
are as follows: less than 10 mg/dl, 10-15 mg/dl, more than 15 mg/dl.  
Among the 200 patients 63 were found to be less than 10 mg/dl, 128 were 
between 10-15 mg/dl, 9 were more than 15 mg/dl.Among the 100 patients in 
ESRD- diabetes mellitus patients, 56 (88.89%) were found to be less than 10 
mg/dl, 41 (32.03%) were between 10-15 mg/dl, 3 (33.33%) were more than 
15 mg/dl. the mean value for the hemoglobin level in ESRD patients is 
9.81mg/dl. Among the 100 patients in NESRD- diabetes mellitus patients, 7 
(11.11%) were found to be less than 10 mg/dl, 87 (67.97%) were between 
10-15 mg/dl, 6 (66.67%) were more than 15 mg/dl. The mean value for the 
hemoglobin level in NESRD patients is 12.3mg/dl 
The distribution of subjects based on Concentration of hemoglobin 
level were found to be statistically significant, which means that there 
exists correlation among the 2 groups with respect to Concentration of 
hemoglobin level in distribution with P value ≤ 0.000 
TABLE 11: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to serum creatinine 
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The Serum creatinine of the subjects included in the study ranges 
between 0-10 mg/dl. So the subjects were divided into three groups which 
are as follows: less than 2 mg/dl, 2-10 mg/dl, more than 10 mg/dl. Among 
the 200 patients, 100 were found to be less than 2 mg/dl, 91 were between 
2-10 mg/dl, 9 were more than 10 mg/dl. Among the 100 patients in ESRD- 
Diabetes Mellitus patients, 0 (0%) were found to be less than 2 mg/dl, 91 
(100%) were between 2-10 mg/dl, 9 (100%) were more than 10 mg/dl. The 
mean value for the Serum creatinine in ESRD patients is 4.334mg/dl. 
Among the 100 patients in NESRD- Diabetes Mellitus patients, 100 (100%) 
were found to be less than 2 mg/dl,  (0%) were between 2-10 mg/dl, 0 (0%) 
were more than 10 mg/dl. the mean value for the Serum creatinine in 
NESRD patients is 0.945mg/dl. 
The distribution of subjects based on Concentration of Serum 
creatinine were found to be statistically significant, which means that there 
exists correlation among the 2 groups with respect to Concentration of 
Serum creatinine in distribution with P value ≤ 0.000. 
TABLE 12: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to blood urea level 
The blood urea level of the subjects included in the study ranges 
between 0-150 mg/dl. So the subjects were divided into three groups which 
are as follows: less than 50 mg/dl, 50-100 mg/dl, more than 100 mg/dl.  
Among the 200 patients, 137 were found to be less than 50 mg/dl, 40 were 
between 50-100 mg/dl, 23 (100%) were more than 100 mg/dl. Among the 
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100 patients in ESRD- diabetes mellitus patients, 37 (27%) were found to be 
less than 50 mg/dl, 40 (100%) were between 50-100 mg/dl, 23 (100%) were 
more than 100 mg/dl. the mean value for the blood urea level in ESRD 
patients is 73.72mg/dl. Among the 100 patients in NESRD- Diabetes 
Mellitus patients, 100 (73%) were found to be less than 50 mg/dl, 0 (0%) 
were between 50-100 mg/dl, 0 (0%) were more than 100 mg/dl. the mean 
value for the blood urea level in ESRD patients is 28.66mg/dl. 
The distribution of subjects based on Concentration of blood urea 
level were found to be statistically significant, which means that there 
exists correlation among the 2 groups with respect to Concentration of blood 
urea level in distribution with P value ≤ 0.000 
TABLE 13: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to medication for Diabetes Mellitus 
The study group consists of 200 subjects, 58 patients had taken metformin, 
95 patients had taken sulphonyl urea and 47 patients had taken insulin. Out 
of the 100 ESRD patients, 52 patients (89.70%) had taken metformin, 40 
(42.10%) patients had taken sulphonyl urea and 8 (17%) patients had taken 
insulin. Among 100 NESRD patients, 6 patients (10.30%) had taken 
metformin, 55 (57.90%) patients had taken sulphonyl urea and 39 (83%) 
patients had taken insulin. 
The distribution of subjects based on medication for Diabetes 
Mellitus were found to be statistically significant, which means that there 
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exists correlation among the 2 groups with respect to medication for 
Diabetes Mellitus in distribution with P value ≤ 0.000 
TABLE 14: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Saburral Tongue 
Among the 200 patients, 24 patients had Saburral Tongue and 176 patients 
did not have Saburral Tongue. Among 100 ESRD patients, 19 (79.20%) had 
Saburral Tongue and 81 (46.00%) patients did not have Saburral Tongue. 
Among 100 NESRD patients, 5 (20.80%) had Saburral Tongue and 95 
(54.00%) patients did not have Saburral Tongue. 
The distribution of subjects based on presence of Saburral Tongue 
were found to be statistically significant, which means that there exists 
correlation among the 2 groups with respect to presence of Saburral Tongue 
in distribution with P value ≤ 0.002 
TABLE 15: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Fissured Tongue 
Among the 200 patients, 4 patients had Fissured Tongue and 196 
patients did not have Fissured Tongue. Among 100 ESRD patients, 2 (50%) 
had Fissured Tongue and 98 (50%) patients did not have Fissured Tongue. 
Among 100 NESRD patients, 2 (50%) had Fissured Tongue and 98 (50%) 
patients did not have Fissured Tongue. 
The distribution of subjects based on Fissured Tongue were found to 
be statistically not significant, which means that there exists no correlation 
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among the 2 groups with respect to Fissured Tongue in distribution with     
P value ≤ 1.000 
TABLE 16: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Smooth Tongue 
Among the 200 patients, 18 patients had smooth Tongue and 182 
patients did not have smooth Tongue. Among 100 ESRD patients, 11 
(61.10%) had smooth Tongue and 89 (48.90%) patients did not have smooth 
Tongue. Among 100 NESRD patients, 7 (38.90%) had smooth Tongue and 
93 (51.10%) patients did not have smooth Tongue. 
The distribution of subjects based on smooth Tongue were found to 
be statistically not significant, which means that there exists no correlation 
among the 2 groups with respect to smooth Tongue in distribution with       
P value ≥ 0.323 
TABLE 17: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Burning Tongue 
Among the 200 patients, 23 patients had Burning Tongue and 177 
patients did not have Burning Tongue. Among 100 ESRD patients, 13 
(56.50%) had Burning Tongue and 87 (49.20%) patients did not have 
Burning Tongue. Among 100 NESRD patients, 10 (43.50%) had Burning 
Tongue and 90 (50.80%) patients did not have Burning Tongue. 
The distribution of subjects based on Burning Tongue were found to 
be statistically not significant, which means that there exists no correlation 
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among the 2 groups with respect to Burning Tongue in distribution with      
P value ≥ 0.506 
TABLE 18: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Candidiasis 
Among the 200 patients, 51 patients had Candidiasis and 149 
patients did not have Candidiasis. Among 100 ESRD patients, 23 (45.10%) 
had Candidiasis and 77 (51.70%) patients did not have Candidiasis. Among 
100 NESRD patients, 28 (54.90%) had Candidiasis and 72 (48.30%) 
patients did not have Candidiasis. 
The distribution of subjects based on Candidiasis were found to be 
statistically not significant, which means that there exists no correlation 
among the 2 groups with respect to Candidiasis in distribution with P value 
≥ 0.417 
TABLE 19: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Dry and Fissured Lips 
Among the 200 patients, 44 patients had Dry and Fissured Lips and 
156 patients did not have Dry and Fissured Lips. Among 100 ESRD 
patients, 22 (50.00%) had Dry and Fissured Lips and 78 (50.00%) patients 
did not have Dry and Fissured Lips. Among 100 NESRD patients, 22 
(50.00%) had Dry and Fissured Lips and 78 (50.00%) patients did not have 
Dry and Fissured Lips. 
The distribution of subjects based on Dry and Fissured Lips were 
found to be statistically not significant, which means that there exists no 
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correlation among the 2 groups with respect to Dry and Fissured Lips in 
distribution with P value ≥ 1.000 
TABLE 20: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Petechiae / Ecchymoses 
Among the 200 patients, 20 patients had Petechiae / Ecchymoses and 
180 patients did not have Petechiae / Ecchymoses. Among 100 ESRD 
patients, 18 (90.00%) had Petechiae / Ecchymoses and 82 (45.60%) patients 
did not have Petechiae / Ecchymoses. Among 100 NESRD patients,             
2 (10.00%) had Petechiae / Ecchymoses and 98 (54.40%) patients did not 
have Petechiae / Ecchymoses. 
The distribution of subjects based on presence of Petechiae / 
Ecchymoses were found to be statistically significant, which means that 
there exists correlation among the 2 groups with respect to presence of 
Petechiae / Ecchymoses in distribution with P value ≤ 0.000 
TABLE 21: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Angular Chelitis 
Among the 200 patients, 13 patients had Angular Chelitis and 187 
patients did not have Angular Chelitis. Among 100 ESRD patients, 4 
(30.80%) had Angular Chelitis and 96 (51.30%) patients did not have 
Angular Chelitis. Among 100 NESRD patients, 9 (69.20%) had Angular 
Chelitis and 91 (48.70%) patients did not have Angular Chelitis. 
The distribution of subjects based on Angular Chelitis were found to 
be statistically not significant, which means that there exists no correlation 
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among the 2 groups with respect to Angular Chelitis in distribution with      
P value ≥ 0.152 
TABLE 22: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Uremic Stomatitis 
Among the 200 patients, 1 patient had Uremic Stomatitis and 199 
patients did not have Uremic Stomatitis. Among 100 ESRD patients, 1 
(100%) had Uremic Stomatitis and 99 (49.70%) patients did not have 
Uremic Stomatitis. Among 100 NESRD patients, 0 (0%) had Uremic 
Stomatitis and 100 (50.30%) patients did not have Uremic Stomatitis. 
The distribution of subjects based on Uremic Stomatitis were found 
to be statistically not significant, which means that there exists no 
correlation among the 2 groups with respect to Uremic Stomatitis in 
distribution with   P value ≥ 0.316 
TABLE 23: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Uremic Fetor 
Among the 200 patients, 53 patients had Uremic Fetor and 147 
patients did not have Uremic Fetor. Among 100 ESRD patients, 52 
(98.10%) had Uremic Fetor and 48 (32.70%) patients did not have Uremic 
Fetor. Among 100 NESRD patients, 1 (1.90%) had Uremic Fetor and 99 
(67.30%) patients did not have Uremic Fetor. 
The distribution of subjects based on presence of Uremic Fetor were 
found to be statistically significant, which means that there exists 
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correlation among the 2 groups with respect to presence of Uremic Fetor in 
distribution with P value ≤ 0.000 
TABLE 24: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Xerostomia 
Among the 200 patients, 82 patients had Xerostomia and 118 
patients did not have Xerostomia. Among 100 ESRD patients, 42 (51.20%) 
had Xerostomia and 58 (49.20%) patients did not have Xerostomia. Among 
100 NESRD patients, 40 (48.80%) had Xerostomia and 60 (50.80%) 
patients did not have Xerostomia. 
The distribution of subjects based on Xerostomia were found to be 
statistically not significant, which means that there exists no correlation 
among the 2 groups with respect to Xerostomia in distribution with P value 
≥ 0.774 
TABLE 25: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Herpes Labialis 
Among the 200 patients, 8 patients had Herpes Labialis and 192 
patients did not have Herpes Labialis. Among 100 ESRD patients, 5 
(62.50%) had Herpes Labialis and 95 (49.50%) patients did not have Herpes 
Labialis. Among 100 NESRD patients, 3 (37.50%) had Herpes Labialis and 
97 (50.50%) patients did not have Herpes Labialis. 
The distribution of subjects based on Herpes Labialis were found to 
be statistically not significant, which means that there exists no correlation 
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among the 2 groups with respect to Herpes Labialis in distribution with       
P value ≥ 0.470 
TABLE 26: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Aphthous Ulcer 
Among the 200 patients, 5 patients had Aphthous Ulcer and 195 
patients did not have Aphthous Ulcer. Among 100 ESRD patients, 1 (20%) 
had Aphthous Ulcer and 99 (50.80%) patients did not have Aphthous Ulcer. 
Among 100 NESRD patients, 4 (80%) had Aphthous Ulcer and 96 (49.20%) 
patients did not have Aphthous Ulcer. 
The distribution of subjects based on Aphthous Ulcer were found to 
be statistically not significant, which means that there exists no correlation 
among the 2 groups with respect to Aphthous Ulcer in distribution with       
P value ≥ 0.174 
TABLE 27: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Pale Mucosa 
Among the 200 patients, 59 patients had Pale Mucosa and 141 
patients did not have Pale Mucosa. Among 100 ESRD patients, 45 (76.30%) 
had Pale Mucosa and 55 (39.00%) patients did not have Pale Mucosa. 
Among 100 NESRD patients, 14 (23.70%) had Pale Mucosa and 86 
(61.00%) patients did not have Pale Mucosa. 
The distribution of subjects based on presence of Pale Mucosa were 
found to be statistically significant, which means that there exists 
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correlation among the 2 groups with respect to presence of Pale Mucosa in 
distribution with P value ≤ 0.000 
TABLE 28: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Unpleasant Taste 
Among the 200 patients, 86 patients had Unpleasant Taste and 114 
patients did not have Unpleasant Taste. Among 100 ESRD patients, 46 
(53.50%) had Unpleasant Taste and 54 (47.40%) patients did not have 
Unpleasant Taste. Among 100 NESRD patients, 40 (46.50%) had 
Unpleasant Taste and 60 (52.60%) patients did not have Unpleasant Taste. 
The distribution of subjects based on Unpleasant Taste were found to 
be statistically not significant, which means that there exists no correlation 
among the 2 groups with respect to Unpleasant Taste in distribution with    
P value ≥ 0.391 
TABLE 29: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Stomatitis Medicamentosa 
Among the 200 patients, 4 patients had Stomatitis Medicamentosa 
and 196 patients did not have Stomatitis Medicamentosa. Among 100 ESRD 
patients, 4 (100%) had Stomatitis Medicamentosa and 96 (49.00%) patients 
did not have Stomatitis Medicamentosa. Among 100 NESRD patients, 0 
(0%) had Stomatitis Medicamentosa and 100 (51.00%) patients did not have 
Stomatitis Medicamentosa . 
The distribution of subjects based on presence of Stomatitis 
Medicamentosa was found to be statistically significant, which means that 
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there exists correlation among the 2 groups with respect to presence of 
Stomatitis Medicamentosa in distribution with P value ≤ 0.043. 
TABLE 30: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Lichen Planus 
Among the 200 patients, 11 patients had Lichen Planus and 189 
patients did not have Lichen Planus. Among 100 ESRD patients, 7 (63.60%) 
had Lichen Planus and 93 (49.20%) patients did not have Lichen Planus. 
Among 100 NESRD patients, 4 (36.40%) had Lichen Planus and 96 
(50.80%) patients did not have Lichen Planus. 
The distribution of subjects based on Lichen Planus were found to be 
statistically not significant, which means that there exists no correlation 
among the 2 groups with respect to Lichen Planus in distribution with         
P value ≥ 0.352 
 
 Tables & Graphs 
 
   
 
88 
Table 1: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Sex 
Group 
Male Female Total 
number 
of 
patients 
P-value 
Number Percentage Number Percentage 
ESRD 41 51.90% 59 48.80% 100 
≥ 0.664 NESRD 38 48.10% 62 51.20% 100 
Total 79 100% 121 100% 200 
 
P- Value is ≥ 0.664, this is statistically not significant 
Table 2: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to age 
 
Group 
 
Age 
Total 
number 
of 
patients 
 
Mean 
(yrs) 
 
P-value 
12-40 yrs 41-60 yrs 61-80 yrs 81-100 yrs 
No % No % No % No % 
ESRD 22 30.56% 59 58.41% 17 70.83% 2 66.67% 100 50.77 
≤ 0.000 NESRD 50 69.44% 42 41.59% 7 29.17% 1 33.33% 100 40.82 
total 72 100% 101 100% 24 100% 3 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
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Table 3: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to habits 
Group 
No habits Smoking Tobacco Total 
number 
of 
patients 
P-
value Number Percentage Number Percentage Number Percentage 
ESRD 60 42.60% 22 62.90% 18 75.00% 100 
≤ 
0.003 
NESRD 81 57.40% 13 37.10% 6 25.00% 100 
Total 141 100% 35 100% 24 100% 200 
 
P- Value is ≤ 0.003; this is statistically very highly significant 
Table 4: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to diet 
 
Group 
Renial Diet Vegetarian Non-Vegetarian Total 
number 
of 
patients 
P-
value Number Percentage Number Percentage Number Percentage 
ESRD 29 27.40% 68 74.70% 3 100.00% 100 
≤ 
0.000 
NESRD 77 72.60% 23 25.30% 0 0.00% 100 
Total 106 100% 91 100% 3 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
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Table 5: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Type of Diabetes Mellitus 
 
Group 
IDDM NIDDM Total 
number 
of 
patients 
P-value 
Number Percentage Number Percentage 
ESRD 17 43.60% 83 51.60% 100 
≥ 0.372 NESRD 22 56.40% 78 48.40% 100 
Total 39 100% 161 100% 200 
 
P- Value is ≥ 0.372, this is statistically not significant 
Table 6: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Duration of Diabetes Mellitus 
 
Duration of Diabetes mellitus    
1-12yrs 13-40yrs 41-60 yrs 61-80 yrs Total 
number 
of 
patients 
Mean 
(yrs) 
P-value 
No % No % No % No % 
ESRD 54 38.58% 45 76.28% 1 100% 0 0% 100 14.39 
≤ 0.000 NESRD 86 61.42% 14 23.72% 0 0% 0 0% 100 5.82 
Total 140 100% 59 100% 1 100% 0 0% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
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Table 7: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to family history of Diabetes Mellitus 
Group 
Family history of Diabetic Mellitus Total 
number 
of 
patients 
P-value Present Absent 
Number Percentage Number Percentage 
ESRD 24 52.20% 76 49.40% 100 
≥ 0.737 NESRD 22 47.80% 78 50.60% 100 
Total 46 100% 154 100% 200 
 
P- Value is ≥ 0.737, this is statistically not significant 
Table 8: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to fasting blood sugar level 
Group 
Fasting blood sugar level 
Total 
number 
of 
patients 
Mean P-value <120 mg/dl 120 to 200 mg/dl > 200 mg/dl 
No % No % No % 
ESRD 30 42.25% 42 53.17% 28 56% 100 161.63 
≥ 0.330 NESRD 41 57.75% 37 46.83% 22 44% 100 153.18 
Total 71 100% 79 100% 50 100% 200 
 
P- Value is ≥ 0.330, this is statistically not significant 
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Table 9: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Hypertension 
 
Group 
Hypertension 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 26 65.00% 74 46.30% 100 
≤ 0.034 NESRD 14 35.00% 86 53.70% 100 
Total 40 100% 160 100% 200 
 
P- Value is ≤ 0.034, this is statistically significant 
Table 10: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Hemoglobin level 
Group 
Hemoglobin (Hb) level 
Total 
number 
of 
patients 
Mean 
(mg/dl) 
P-value <10 mg/dl 10 to 15 mg/dl > 15 mg/dl 
No % No % No % 
ESRD 56 88.89% 41 32.03% 3 33.33% 100 9.81 
≤ 0.000 NESRD 7 11.11% 87 67.97% 6 66.67% 100 12.3 
Total 63 100% 128 100% 9 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
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Table 11: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Serum Creatinine 
 
 
Serum creatinine 
Total 
number of 
patients 
Mean 
(mg/dl) 
P-value <2 mg/dl 2 to 10 mg/dl >10 mg/dl 
No % No % No % 
ESRD 0 0 91 100% 9 100% 100 4.334 
≤ 0.000 NESRD 100 100% 0 0 0 0% 100 0.945 
Total 100 100% 91 100% 9 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
Table 12: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Blood Urea Level 
 
Blood Urea Level 
Total 
number 
of 
patients 
Mean 
(mg/dl) 
P-value 
<50 mg/dl 50 to 100 mg/dl > 100 mg/dl 
No % No % No % 
ESRD 37 27% 40 100% 23 100% 100 73.72 
≤ 0.000 NESRD 100 73% 0 0 0 0 100 28.66 
Total 137 100% 40 100% 23 100% 200 
P- Value is ≤ 0.000; this is statistically very highly significant 
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Table 13: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to medication for Diabetes Mellitus 
Group 
Metformin Sulphonylurea Insulin  
Total 
P-value 
Number Percentage Number Percentage Number Percentage 
ESRD 52 89.70% 40 42.10% 8 17.00% 100 
≤ 0.000 NESRD 6 10.30% 55 57.90% 39 83.00% 100 
Total 58 100% 95 100% 47 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
Table 14: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Saburral Tongue 
 
Group 
Saburral tongue 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 19 79.20% 81 46.00% 100 
≤ 0.002 NESRD 5 20.80% 95 54.00% 100 
Total 24 100% 176 100% 200 
 
P- Value is ≤ 0.002; this is statistically very highly significant 
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Table 15: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Fissured Tongue 
 
Group 
Fissured Tongue 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 2 50.00% 98 50.00% 100 
≥ 1.000 NESRD 2 50.00% 98 50.00% 100 
Total 4 100% 196 100% 200 
 
P- Value is ≥ 1.000, this is statistically not significant 
Table 16: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Smooth Tongue 
 
Group 
Smooth Tongue 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 11 61.10% 89 48.90% 100 
≥ 0.323 NESRD 7 38.90% 93 51.10% 100 
Total 18 100% 182 100% 200 
 
P- Value is ≥ 0.323, this is statistically not significant 
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Table 17: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Burning Tongue 
 
Group 
Burning Tongue Total 
number 
of 
patients 
P-value Present Absent 
Number Percentage Number Percentage 
ESRD 13 56.50% 87 49.20% 100 
≥0.506 NESRD 10 43.50% 90 50.80% 100 
Total 23 100% 177 100% 200 
 
P- Value is ≥ 0.506, this is statistically not significant 
Table 18: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Candidiasis 
Group 
Candidiasis 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 23 45.10% 77 51.70% 100 
≥ 0.417 NESRD 28 54.90% 72 48.30% 100 
Total 51 100% 149 100% 200 
 
P- Value is ≥ 0.417, this is statistically not significant 
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Table 19: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Dry and Fissured Lips 
 
Group 
Dry and Fissured Lips 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 22 50.00% 78 50.00% 100 
1.000 NESRD 22 50.00% 78 50.00% 100 
Total 44 100% 156 100% 200 
 
P- Value is ≥ 1.000, this is statistically not significant 
 
Table 20: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Petechiae / Ecchymoses 
Group 
Petechiae / Ecchymoses 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 18 90.00% 82 45.60% 100 
≤ 0.000 NESRD 2 10.00% 98 54.40% 100 
Total 20 100% 180 100% 200 
 
P- Value is ≤ 0.000, this is statistically very highly significant 
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Table 21: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Angular Chelitis 
 
Group 
Angular Chelitis Total 
number 
of 
patients 
P-value Present Absent 
Number Percentage Number Percentage 
ESRD 4 30.80% 96 51.30% 100 
≥0.152 NESRD 9 69.20% 91 48.70% 100 
Total 13 100% 187 100% 200 
 
P- Value is ≥ 0.152, this is statistically not significant 
Table 22: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Uremic Stomatitis 
Group 
Uremic Stomatitis Total 
number 
of 
patients 
P-value Present Absent 
Number Percentage Number Percentage 
ESRD 1 100.00% 99 49.70% 100 
≥0.316 NESRD 0 0.00% 100 50.30% 100 
Total 1 100% 199 100% 200 
 
P- Value is ≥ 0.316, this is statistically not significant 
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Table 23: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Uremic Fetor 
 
Group 
Uremic Fetor 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 52 98.10% 48 32.70% 100 
≤ 0.000 NESRD 1 1.90% 99 67.30% 100 
Total 53 100% 147 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
Table 24: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Xerostomia 
Group 
Xerostomia 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 42 51.20% 58 49.20% 100 
≥ 0.774 NESRD 40 48.80% 60 50.80% 100 
Total 82 100% 118 100% 200 
 
P- Value is ≥ 0.774, this is statistically not significant 
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Table 25: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Herpes Labialis 
 
Group 
Herpes Labialis 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 5 62.50% 95 49.50% 100 
≥ 0.470 NESRD 3 37.50% 97 50.50% 100 
Total 8 100% 192 100% 200 
 
P- Value is ≥ 0.470, this is statistically not significant 
 
Table 26: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Aphthous Ulcer 
Group 
Aphthous Ulcer 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 1 20.00% 99 50.80% 100 
≥ 
0.174 
NESRD 4 80.00% 96 49.20% 100 
Total 5 100% 195 100% 200 
 
P- Value is ≥ 0.174, this is statistically not significant 
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Table 27: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Pale Mucosa 
 
Group 
Pale Mucosa 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 45 76.30% 55 39.00% 100 
≤ 0.000 NESRD 14 23.70% 86 61.00% 100 
Total 59 100% 141 100% 200 
 
P- Value is ≤ 0.000; this is statistically very highly significant 
TABLE 28: Distribution of ESRD and NESRD among Diabetes 
Mellitus patients with relation to Unpleasant Taste 
 Group 
Unpleasant Taste 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 46 53.50% 54 47.40% 100 
≥0.391 NESRD 40 46.50% 60 52.60% 100 
Total 86 100% 114 100% 200 
 
P- Value is ≥ 0.391, this is statistically not significant 
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Table 29: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Stomatitis Medicamentosa 
 
Group 
Stomatitis Medicamentosa 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 4 100.00% 96 49.00% 100 
≤ 0.043 NESRD 0 0.00% 100 51.00% 100 
Total 4 100% 196 100% 200 
 
P- Value is ≤ 0.043, this is statistically significant 
Table 30: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Lichen Planus 
 
Group 
Lichen Planus 
Total 
number 
of 
patients 
P-value 
Present Absent 
Number Percentage Number Percentage 
ESRD 7 63.60% 93 49.20% 100 
≥ 0.352 NESRD 4 36.40% 96 50.80% 100 
Total 11 100% 189 100% 200 
 
P- Value is ≥ 0.352, this is statistically not significant 
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Graph 1: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Sex 
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Graph 2: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Age 
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Graph 3: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Habits 
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Graph 4: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Diet 
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Graph 5: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Type of Diabetes Mellitus 
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Graph 6: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Duration of Diabetes Mellitus 
 
 Tables & Graphs 
 
   
 
106
Graph 7: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to family history of Diabetes Mellitus 
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Graph 8: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Fasting Blood Sugar Level 
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Graph 9: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Hypertension 
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Graph 10: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Hemoglobin Level 
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Graph 11: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Serum Creatinine 
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Graph 12: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Blood Urea Level 
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Graph 13: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to medication for Diabetes Mellitus 
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Graph 14: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Saburral Tongue 
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Graph 15: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Fissured Tongue 
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Graph 16: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Smooth Tongue 
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Graph 17: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Burning Tongue 
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Graph 18: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Candidiasis 
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Graph 19: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Dry and Fissured Lips 
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Graph 20: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Petechiae / Ecchymoses 
90.00%
10.00%
45.60%
54.40%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
P res ent Abs ent
E S R D
NE S R D
 
 Tables & Graphs 
 
   
 
113
Graph 21: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Angular Chelitis 
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Graph 22: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Uremic Stomatitis 
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Graph 23: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Uremic Fetor 
98.10%
1.90%
32.70%
67.30%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
P res ent Abs ent
E S R D
NE S R D
 
Graph 24: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Xerostomia 
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Graph 25: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Herpes Labialis 
62.50%
37.50%
49.50% 50.50%
0%
10%
20%
30%
40%
50%
60%
70%
P res ent Abs ent
E S R D
NE S R D
 
Graph 26: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Aphthous Ulcer 
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Graph 27: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Pale Mucosa 
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Graph 28: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Unpleasant Taste 
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Graph 29: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Stomatitis Medicamentosa 
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Graph 30: Distribution of ESRD and NESRD among Diabetes Mellitus 
patients with relation to Lichen Planus 
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Diabetic Nephropathy is becoming a major problem as the incidence 
of diabetes is increasing. Diabetes is currently the most common cause of 
renal failure in the Western World. The pathways leading to Diabetic 
Nephropathy are thought to involve both genetic and environmental factors 
intertwined in a complex fashion Glycaemic control are important for the 
development of Diabetic Nephropathy. This fact was established by the 
landmark Diabetes Control and Complications Trial (DCCT)
 107,108
 
The incidence of diabetes is increasing word-wide, with subsequent 
increase in the incidence of Diabetic Nephropathy. The earliest clinical 
evidence of Diabetic Nephropathy is microalbuminuria. Progression from 
microalbuminuria to overt nephropathy occurs in 20-40% within a 10-year 
period with approximately 20% of these patients progressing to end-stage 
renal disease. End-stage renal disease develops in 50% of type 1 diabetes 
patients with overt nephropathy within 10 years and in more than 75% by 20 
years in the absence of treatment. In Type-2 Diabetes, a greater proportion 
of patients have microalbuminuria and overt nephropathy at or shortly after 
diagnosis of diabetes
73
.
  
Patients with diabetes undergoing dialysis have a 22% and 15% 
higher mortality at one year and five years, respectively, when compared 
with patients without diabetes, and specifically the first-year mortality of 
patients with Type-2 Diabetes who require dialysis exceeds 20%
73
. 
Patients with macroalbuminuria, and especially those with ESRD, 
are at great risk of cardiovascular events and premature death. Premature 
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death is thus a competing outcome to ESRD in patients with diabetes and 
macroalbumniuria
107,108
. 
With respect to our study it is important not only to 
diferentiate between ESRD and NESRD in Diabetes Mellitus 
patients by oral mucosal lesion, signs and symptoms, but also to 
identify those with asymptomatic ESRD, who may require treatment 
at the earliest to prevent complications.  
Investigations used in our study are   
 Evaluation of Fasting Blood Sugar 
 Evaluation of Hemoglobin Level 
 Evaluation of Serum Creatinine 
 Evaluation of Blood Urea Level. 
This is in accordance with the study conducted by De La Rosa 
García E et al
66
 in 2006. 
This study is to assess oral signs, symptoms and oral lesions type 
and prevalence, in diabetic patients with End Stage Renal Disease (ESRD-
DM) and compare them with analogous findings in Non-End Stage Renal 
Disease (NESRD-DM) group. 
This study was conducted between June 2010 to May 2011 in the 
department of Oral Medicine and Radiology of Ragas Dental College and 
Hospital, and Voluntary Health Services, Adyar, Chennai 
A comparative study was conducted in 200 Diabetic patients, who 
are diagnosed as having Non-End Stage Renal Disease and End Stage Renal 
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Disease undergoing dialysis will be taken up for the study. These patients 
will undergo general clinical examination to exclude HIV. Patients are 
examined for the presence of intra oral manifestations of Diabetic patients 
with End Stage Renal Disease (ESRD-DM) and with Non-End Stage Renal 
Disease (NESRD-DM) like saburral tongue, smooth tongue, burning tongue, 
candidiasis, dry and fissured lips, petechiae or ecchymoses, ulcerative or 
uremic stomatitis, herpes simplex, angular cheilitis, uremic fetor, 
xerostomia, pale mucosa. 
STUDY ANALYSIS 
ACCORDING TO SEX OF THE SUBJECTS 
 In the present study, among the 200 subjects, 79 patients were male 
and 121 patients were female. Out of the 100 ESRD patients, 41 patients 
(51.90%) are found to be male and 59 patients (48.80%) are found to be 
female .Among the 100 NESRD patients, 38 patients (48.10%) are male and 
62 patients (51.20%) were female. with a P-value of ≤ 0.664 which is 
statistically not significant. Thus a negative correlation between the 2 
groups with respect to sex in the distribution is seen 
In our study, with respect to Sex, the female patients were more 
because of greater possibility of small sample size. 
This is not in accordance with the study conducted by Zohreh 
Hajheydari, Atieh Makhlough
69
, 43 (42.6%) women and 58 (57.4%) men , 
Gall et al
71
 found that males had a 2.6 times greater risk of developing 
incipient or overt nephropathy, Choy BY et al
72
 found that for ESRD 
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patients, the male/female ratio was reported to be about 1:1 for Diabetes 
Patients. 
ACCORDING TO AGE GROUP 
In the present study, among 200 patients, 72 were in age group of 
12-40 years, 101 patients were in age group of 41-60 years, 24 patients were 
in age group of 61-80 years, and 3 patients were in the age group of 81-100 
years. Among the 100 patients in ESRD- Diabetes Mellitus patients, 22 
(30.56%) were between 12-40yrs, 59 (58.41%) were between 41- 60 yrs, 17 
(70.83%) were between 61-80 yrs, 2 (66.67%) were between 81-100 yrs, 
Among the 100 patients in NESRD- Diabetes Mellitus patients, 50 (69.44%) 
were between 12- 40 yrs, 42 (41.59%) were between 41-60 yrs, 7 (29.17%) 
were between 61-80 yrs, 1 (33.33%) were between 81-100 yrs.  
The mean age group affected by ESRD is 50.77; the mean age group 
affected by NESRD is 40.82, with a P-value of ≤ 0.000 which is statistically 
very highly significant. Thus a positive correlation between the 2 groups 
with respect to age in the distribution is seen.. 
This is in accordance with the study conducted by Thorman R, 
Neovius M and Hylander B
75
, on 101 patients and found 43 (42.6%) were 
women and 58 (57.4%) were men with a mean age of 50.0 ± 12.3 years, 
Belmiro Cavalcanti do Egito Vasconcelos et al
28
 conducted a study on 30 
patients, 40% were below 60 years of age, and 60% were older than 60 
years, Chi-yuan Hsu et al
67
 found the prevalence of chronic renal 
insufficiency among older adults was 10-fold that of younger individuals . 
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However, younger individuals with chronic renal insufficiency were about 
3-fold more likely to progress to ESRD. 
ACCORDING TO HABIT AMONG THE STUDY SUBJECTS 
In the present study, among the 200 patients, 35 patients have 
smoking habits, and 24 patients have tobacco related habits. Among 100 
ESRD patients, 22 (62.90%) patients have smoking habits, and 18 (75%) 
patients have tobacco related habits. Among 100 NESRD patients, 13 
(37.10%) patients have smoking habits, and 6 (25%) patients have tobacco 
related habits, with a P-value of ≤ 0.003 which is statistically highly 
significant. Thus a positive correlation between the 2 groups with respect to 
habits in the distribution is seen 
This is in accordance with the study conducted by Olugbenga. E. 
Ayodele et al
73
, found that Smoking with a P-value ≤ 0.001, causes a 
substantial increase in the risk of both micro- and macrovascular diseases in 
Diabetes. Smoking is an independent risk factor for the development of 
Diabetic Nephropathy and is associated with an accelerated loss of renal 
function, an increased risk for ESRD, and decreased survival on 
commencement of dialysis. Loss of renal function is slower in those who 
stopped smoking. Cessation of smoking alone may reduce the risk of 
progression by 30% in patients with Type-2 Diabetes 
ACCORDING TO DIET AMONG THE STUDY SUBJECTS 
In the present study, among the 200 patients, 106 patients were on 
renal diet, 91 patients were on vegetarian diet and 3 patients were on Non 
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vegetarian diet. Among 100 ESRD patients, 29 patients (27.4%) were on 
renal diet, 68 patients (74.70%) were on vegetarian diet and 3 (100%) 
patients were on Non vegetarian diet. Among 100 NESRD patients, 77 
patients (72.6%) were on renal diet, 23 patients (25.30%) were on 
vegetarian diet and 0 (0%) patients were on Non vegetarian diet.  
With a P-value of ≤ 0.000 which is statistically very highly 
significant, a positive correlation between the 2 groups with respect to habits 
in the distribution is seen 
 This is in accordance with the study conducted by Jorge l Gross et 
al 
74
 in 108 patients, that dietary protein restriction slowed the progression 
of Diabetic Nephropathy in patients with type 1 diabetes. More recently, a 
4-year randomized controlled trial in 82 patients with type 1 diabetes with 
progressive Diabetic Nephropathy showed that a moderately low–protein 
diet (0.9 g / kg / day) reduced the risk of end-stage renal disease or death by 
76%. 
ACCORDING TO TYPE OF DIABETES MELLITUS AMONG THE 
STUDY SUBJECTS 
In this present study, among the 200 patients, 39 patients were 
IDDM (Insulin– Dependent Diabetes Mellitus) and 161 patients were 
NIDDM (Non Insulin – Dependent Diabetes Mellitus). Among 100 ESRD 
patients, 17 (43.6%) were IDDM (Insulin – Dependent Diabetes Mellitus) 
patients and 83 (51.60%) were NIDDM (Non Insulin – Dependent Diabetes 
Mellitus) patients. Among 100 NESRD patients, 22 (56.4%) were IDDM 
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(Insulin – Dependent Diabetes Mellitus) patients and 78 (48.4%) were 
NIDDM (Non Insulin – Dependent Diabetes Mellitus) patients, with a P-
value of ≥ 0.372 which is statistically not significant. Thus a negative 
correlation between the 2 groups with respect to type of Diabetes Mellitus in 
the distribution is seen 
In our study, with respect to type of Diabetes Mellitus, the NIDDM 
(Non Insulin – Dependant Diabetes Mellitus) patients were affected more 
with ESRD.  
This is in accordance with the study conducted by Ritz E, Bergis K, 
Strojek K and Keller C
78
, found that Diabetic Nephropathy in patients with 
Type II Diabetes has become the most frequent cause of End stage Renal 
Failure in Germany. 
ACCORDING TO DURATION OF DIABETES MELLITUS AMONG 
THE STUDY SUBJECTS 
In this present study, among the 200 patients ,140 were found to be 
less than 12 yrs, 59 were between 12-40yrs, 1 (100%) were between 40- 60 
yrs, 0 (0%) were between 60-80 yrs. Among the 100 patients in ESRD- 
Diabetes Mellitus patients, 54 (38.58%) were found to be less than 12 yrs, 
45 (76.28%) were between 12-40yrs, 1 (100%) were between 40- 60 yrs, 0 
(0%) were between 60-80 yrs. Among the 100 patients in NESRD- Diabetes 
Mellitus patients, 86 (61.42%) were found to be less than 12 yrs, 14 
(23.72%) were between 12- 40 yrs, 0 (0%) were between 40-60 yrs, 0 (0%) 
were between 60-80 yrs, with a P-value of ≥ 0.000 which is statistically very 
      Discussion 
 
125 
 
highly significant. Thus a positive correlation between the 2 groups with 
respect to duration of Diabetes Mellitus in the distribution is seen 
In our study, with respect to duration of Diabetes Mellitus, the mean 
duration of Diabetes Mellitus age group affected by ESRD is 14.39 years 
and the mean duration of Diabetes Mellitus group affected by NESRD is 
5.82 years. 
This is in accordance with the study conducted by Gábor L. 
Kovács
76
 in which he found that patients who have Type 1 diabetes with 
nephropathy and hypertension, 50% will go on to develop end-stage renal 
disease within 10 years. 80% of people who have Type 1 diabetes and 
microalbuminuria will progress to overt nephropathy, whereas only 20-40% 
of those with Type 2 Diabetes over a period of 15 years will progress. 
 E. de la Rosa García et al 
93
 conducted a study on 233 patients, In 
133 ESRD DM patients, the median known duration of diabetes before 
dialysis was 17 years. 
ACCORDING TO FAMILY HISTORY DIABETES MELLITUS 
AMONG THE STUDY SUBJECTS 
In this present study, among the 200 patients, 46 patients had family 
history of Diabetes Mellitus. Among 100 ESRD patients, 24 (52.2%) had 
family history of Diabetes Mellitus. Among 100 NESRD patients, 22 
(47.8%) had family history of Diabetes Mellitus, with a P-value of ≥ 0.737 
which is statistically not significant. Thus a negative correlation between the 
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2 groups with respect to family history of Diabetes Mellitus in the 
distribution is seen 
This is not in accordance with the study conducted by Barry I 
Freedman et al 
79
 Family histories were obtained from 4365 dialysis 
patients (83% of those eligible), and 856 (20%) reported having a family 
history of ESRD.  
ACCORDING TO HYPERTENSION AMONG THE STUDY 
SUBJECTS: 
In this present study, among the 200 patients, 40 patients were 
hypertensive. Among 100 ESRD patients, 26 (65%) were hypertensive 
patients. Among 100 NESRD patients, 14 (35%) were hypertensive patients. 
with a P-value of ≥ 0.030 which is statistically significant. Thus a positive 
correlation between the 2 groups with respect to hypertension in the 
distribution is seen 
This is in accordance with the study conducted by Britt B. 
Newsome et al 
77
, on 87,094 patients, found the history of hypertension (P-
value is 0.01) was statistically significant. 
ACCORDING TO FASTING BLOOD SUGAR LEVEL AMONG THE 
STUDY SUBJECTS: 
In this present study, among the 200 patients,71 were found to be 
less than 120 mg/dl, 79 were between 120-200 mg/dl, 50 were more than 
200 mg/dl. Among the 100 patients in ESRD- Diabetes Mellitus patients, 30 
(42.25%) were found to be less than 120 mg/dl, 42 (53.17%) were between 
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120-200 mg/dl, 28 (56%) were more than 200 mg/dl. Among the 100 
patients in NESRD- Diabetes Mellitus patients, 41 (57.75%) were found to 
be less than 120 mg/dl, 37 (46.83%) were between 120-200 mg/dl, 22 (44%) 
were more than 200 mg/dl, with a P-value of ≥ 0.330 which is statistically 
not significant. Thus a negative correlation between the 2 groups with 
respect to fasting blood sugar level in the distribution is seen 
The mean value for the fasting blood sugar level in ESRD patients is 
161.63mg/dl. The mean value for the fasting blood sugar level in NESRD 
patients is 153.18mg/dl 
This is not in accordance with the study conducted by Vesterinen M
 
et al
89
, in CKD patients with Diabetes Mellitus had poor glycemic control as 
expected (mean HbA1C) 8.0%  the normal value being  ≤  5.9%, with a       
P-value <0.01. 
ACCORDING TO HEMOGLOBIN LEVEL AMONG THE STUDY 
SUBJECTS 
In this present study, among the 200 patients 63 were found to be 
less than 10 mg/dl, 128 were between 10-15 mg/dl, 9 were more than 15 
mg/dl.Among the 100 patients in ESRD- Diabetes Mellitus patients, 56 
(88.89%) were found to be less than 10 mg/dl, 41 (32.03%) were between 
10-15 mg/dl, 3 (33.33%) were more than 15 mg/dl. Among the 100 patients 
in NESRD- Diabetes Mellitus patients, 7 (11.11%) were found to be less 
than 10 mg/dl, 87 (67.97%) were between 10-15 mg/dl, 6 (66.67%) were 
more than 15 mg/dl. with a P-value of ≥ 0.000 which is statistically very 
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highly significant. Thus a positive correlation between the 2 groups with 
respect to hemoglobin level in the distribution is seen 
The mean value for the hemoglobin level in ESRD patients is 
9.81mg/dl. The mean value for the hemoglobin level in NESRD patients is 
12.3mg/dl 
This is in accordance with the study conducted by Francois Madore 
et Al
70
 found variables of nutritional status in terms of serum albumin and 
Creatinine concentration, and the dose of dialysis -urea reduction ratio were 
found to be significantly associated with Hemoglobin concentration             
(P < 0.001). Age, race, and gender were also found to be significantly 
associated with haemoglobin concentrations (P < 0.001) and concluded that 
Anemia may be predictive of an increased risk of mortality in some 
hemodialysis patients. 
ACCORDING TO SERUM CREATININE LEVEL AMONG THE 
STUDY SUBJECTS 
In this present study, among the 200 patients, 100 were found to be 
less than 2 mg/dl, 91 were between 2-10 mg/dl, 9 were more than 10 mg/dl. 
Among the 100 patients in ESRD- Diabetes Mellitus patients, 0 (0%) were 
found to be less than 2 mg/dl, 91 (100%) were between 2-10 mg/dl, 9 
(100%) were more than 10 mg/dl. Among the 100 patients in NESRD- 
Diabetes Mellitus patients, 100 (100%) were found to be less than 2 mg/dl,  
(0%) were between 2-10 mg/dl, 0 (0%) were more than 10 mg/dl. with a P-
value of ≥ 0.000 which is statistically very highly significant. Thus a 
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positive correlation between the 2 groups with respect to concentration of  
serum creatinine level in the distribution is seen 
The mean value for the Serum Creatinine in ESRD patients is 
4.334mg/dl. The mean value for the Serum Creatinine in NESRD patients is 
0.945mg/dl. 
This is in accordance with the study conducted by De La Rosa 
García E et al
66
 in 2006, evaluated 229 individuals, Group A: ESRD DM 
on dialysis, and group B: Non-ESRD DM categorized as patients with 
serum creatinine <2.0 mg/dl.  
 Sanjay Kumar Agarwal et al
51
 who,  stated that serum creatinine 
persistently >1.8mg% for 8–12 weeks in the absence of any reversible factor 
was the criterion to diagnose Chronic Renal Failure, Agarwal et al
84
 
screened 4900 persons in urban communities of Delhi and found a .79% 
point prevalence of persons with Serum Creatinine more than1.8 mg/dL.  
A M El Nahas et al
83
 stated that the ratio of plasma urea to 
creatinine concentration accurately reflected the dietary protein intake: it 
rose to 110 during the high protein diet and subsequently fell to 40  during 
the low protein diet with a P-value of  <0 025. 
ACCORDING TO BLOOD UREA LEVEL AMONG THE STUDY 
SUBJECTS 
In this present study, among the 200 patients, 137 were found to be 
less than 50 mg/dl, 40 were between 50-100 mg/dl, 23 (100%) were more 
than 100 mg/dl. Among the 100 patients in ESRD- Diabetes Mellitus 
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patients, 37 (27%) were found to be less than 50 mg/dl, 40 (100%) were 
between 50-100 mg/dl, 23 (100%) were more than 100 mg/dl. Among the 
100 patients in NESRD- Diabetes Mellitus patients, 100 (73%) were found 
to be less than 50 mg/dl, 0 (0%) were between 50-100 mg/dl, 0 (0%) were 
more than 100 mg/dl. with a P-value of ≥ 0.000 which is statistically very 
highly significant. Thus a positive correlation between the 2 groups with 
respect to concentration of blood urea level in the distribution is seen 
The mean value for the blood urea level in ESRD patients is 
73.72mg/dl. The mean value for the blood urea level in NESRD patients is 
28.66mg/dl 
There were no studies with regard to blood urea level in ESRD and 
NESRD - Diabetes Mellitus patients to correlate with the findings of our 
study. 
ACCORDING TO MEDICATION FOR DIABETES MELLITUS 
AMONG THE STUDY SUBJECTS 
In this study group, among 200 subjects, 58 patients had taken 
metformin, 95 patients had taken sulphonyl urea and 47 patients had taken 
insulin. Out of the 100 ESRD patients, 52 patients (89.70%) had taken 
metformin, 40 (42.10%) patients had taken sulphonyl urea and 8 (17%) 
patients had taken insulin. Among 100 NESRD patients, 6 patients (10.30%) 
had taken metformin, 55 (57.90%) patients had taken sulphonyl urea and 39 
(83%) patients had taken insulin, with a P-value of ≥ 0.000 which is 
statistically very highly significant. Thus a positive correlation between the 
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2 groups with respect to medication for Diabetes Mellitus in the distribution 
is seen. 
In this present study also patients who have been having serum 
creatinine level ≥ 2.0 mg /dl have been under the medication of metformin, 
and sulphonyl urea 
This is in accordance with the study conducted by Jorge l. Gross  et 
al
74
. They stated that Metformin should not be used when Serum Creatinine 
is >1.5 mg/dl in men and >1.4 mg/dl in women due to the increased risk of 
lactic acidosis. Sulfonylureas and their metabolites except glimepiride, are 
eliminated via renal excretion and should not be used in patients with 
decreased renal function Thus, most type 2 diabetic patients with Diabetic 
Nephropathy should be treated with insulin. 
Janelle C Nisbet et al
97
, found that life-threatening lactic acidosis 
can occur, caused by accumulation of metformin, and that risk factors for 
this include renal impairment, old age and doses over 2 g per day. . The 
estimated prevalence of life-threatening lactic acidosis is one to five cases 
per 1, 00,000 with mortality in reported cases up to 50%. 
Devasmita Choudhury et al
98
., suggested the Use of metformin and 
the first-generation sulfonylurea agents chlorpropamide, tolbutamide and 
tolazamide, as well as the α-glucosidase inhibitors acarbose and miglitol, 
should be avoided in patients with advanced CKD or ESRD, in light of their 
association with metabolic acidosis and prolonged hypoglycemia. 
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Abe M, et al
94 
stated that Conventional oral hypoglycemic agents, 
such as sulfonylurea (SU), are not suitable due to the risk of prolonged 
hypoglycemia; furthermore, metformin is contraindicated for moderate to 
advanced CKD,  
Jean-Franc¸ois Yale
95
,
 
found that Insulin also can be used safely in 
renal failure 
THE PREVALANCE OF ORAL MUCOSAL LESIONS AMONG THE 
STUDY SUBJECTS 
In this present study, among the 200 patients, 24 patients had 
Saburral Tongue (p value ≤ 0.002), 4 patients had Fissured Tongue (P value 
≤ 1.000), 18 patients had smooth Tongue (P value ≥ 0.323), 23 patients had 
burning Tongue (P value ≥ 0.506), 51 patients had Candidiasis (P value ≥ 
0.417), 44 patients had Dry and Fissured Lips (P value ≥ 1.000), 20 patients 
had Petechiae / Ecchymoses (P value ≤ 0.000), 13 patients had Angular 
Chelitis (P value ≥ 0.152) , 1 patients had Uremic Stomatitis (P value ≥ 
0.316), 53 patients had Uremic Fetor (P value ≤ 0.000), 82 patients had 
Xerostomia (P value ≥ 0.774), 8 patients had Herpes Labialis (P value ≥ 
0.470), 5 patients had Aphthous Ulcer (P value ≥ 0.174), 59 patients had 
Pale Mucosa (P value ≤ 0.000), 86 patients had Unpleasant Taste (P value ≥ 
0.391), 4 patients had Stomatitis Medicamentosa (P value ≤ 0.043), 11 
patients had Lichen Planus (P value ≥ 0.352).   
Among 100 ESRD patients, 19 (79.20%) had Saburral Tongue, 2 
(50%) had Fissured Tongue, 11 (61.10%) had smooth Tongue, 13 (56.50%) 
      Discussion 
 
133 
 
had Burning Tongue, , 23 (45.10%) had Candidiasis, 22 (50.00%) had Dry 
and Fissured Lips, 18 (90.00%) had Petechiae / Ecchymoses, 4 (30.80%) 
had Angular Chelitis, , 1(100%) patients had Uremic Stomatitis, 52 
(98.10%) had Uremic Fetor, 42 (51.20%) had Xerostomia 5 (62.50%) had 
Herpes Labialis, 1 (20%) had Aphthous Ulcer, 45 (76.30%) had Pale 
Mucosa, 46 (53.50%) had Unpleasant Taste, 4 (100%) had Stomatitis 
Medicamentosa, 7 (63.60%) had Lichen Planus.  
Among 100 NESRD patients, 5 (20.80%) had Saburral Tongue, 2 
(50%) had Fissured Tongue, 7 (38.90%) had smooth Tongue, 10 (43.50%) 
had Burning Tongue, 28 (54.90%) had Candidiasis, 22 (50.00%) had Dry 
and Fissured Lips, 2 (10.00%) had Petechiae / Ecchymoses, 9 (69.20%) had 
Angular Chelitis, 0 (0%) patients had Uremic Stomatitis  , 1 (1.90%) had 
Uremic Fetor, 40 (48.80%) had Xerostomia, 3 (37.50%) had Herpes 
Labialis, 4 (80%) had Aphthous Ulcer, 14 (23.70%) had Pale Mucosa, 40 
(46.50%) had Unpleasant Taste , 0 (0%) had Stomatitis Medicamentosa, 4 
(36.40%) had Lichen Planus.   
This is in accordance with the study conducted by Shu-Fen Chuang 
et al
81
 in which they found that the incidence of uremic odor in CRF 
patients with Diabetes Mellitus (27.9%). Incidence of mucosal petechia / 
ecchymosis was 20.9% in CRF patients with Diabetes Mellitus. 
De La Rosa García E et al
66
 evaluated 229 individuals,. Two adult 
groups were studied: Group A: ESRD DM on dialysis, and group B: non-
ESRD DM (Serum Creatinine <2.0 mg/dl). group A 99, and group B 130 
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pts. Signs and symptoms prevalence was higher in group A:  uremic breath 
(48.5%), unpleasant taste (45.5%) and Xerostomia (44.4%) being the most 
frequent ones. Oral Lesions were also more prevalent in group A. The most 
frequent Oral Lesions were dry, fissured lips (28.3%), saburral tongue 
(18.2%) and candidiasis (17.2%). No difference was found in candidiasis 
prevalence between groups. Candidiasis was found associated to xerostomia 
and smooth tongue only in group A. The high prevalence of uremic fetor, 
xerostomia, saburral tongue and candidiasis in group A, could be tried as 
warning signs on the possibility of non diagnosed advanced renal disease in 
other diabetic patients, 
De la Rosa-García E et al
91
, performed a study in 90 patients 
Saburral tongue (ST) was found in 22% of the patients. 
P. Mosannen Mozaffari et al
82 
stated that, one of the early 
symptoms may be a bad metallic taste and unpleasant odor in the mouth 
particularly in the morning. This uremic fetor, an ammoniacal odor is a 
typical sign of all uremic patient. Four of 300 patients with uremia were 
observed to have probable uremic stomatitis in the 1930s, while in 1964 
another 4 affected patients were reported from a group of 262 patients with 
renal disease 
But  not in accordance with study conducted by Neovius M and 
Hylander B et al
75
, on 101 patients and found oral fungal infection (OFI) 
was found in 32% of the ESRD patients and 11% of the controls (P=0.007), 
angular cheilitis, were found in 37% of the patients with OFI (P=0.0002). 
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Udayakumar P et al 
80
 conducted a study on One hundred patients 
with CRF on hemodialysis and found Oral changes included macroglossia 
with teeth markings (35%), xerostomia (31%), ulcerative stomatitis (29%), 
angular cheilitis (12%) and uremic breath (8%). Ulcerative stomatitis seen 
in 29% is reported to occur in patients with blood urea level more than 
150mg/ml. 
Sowell SB
86
, Carl W and Wood RH
 87
, Hovinga J et al
88
 found 
Uremic stomatitis is often a clinical finding in cases of advanced disease.  
Gavaldá et al
90
 examined the oral mucosa of individuals with 
chronic renal failure and noted several mucosal lesions, uremic stomatitis 
and Candida infections in 37% of these patients 
Thorman R et al
75
 evaluated 93 ESRD patients and 45 age- and 
gender-matched controls OFI was found in 32% of the ESRD patients and 
11% of the controls (P-value is 0.007), 
Safia A. Al-Attas et al
92
 conducted a study on 150 Diabetics. They 
found that the number of patients with candidal carriage from the oral cavity 
was higher in patients with type 1 diabetes than in type 2 (P=.003), 
E. de la Rosa García et al
93
 conducted a study  on ESRD DM and 
DM groups, in that order, consisting of 103 and 130 patients respectively 
45.6% and 26.9% (p = 0.003) reported unpleasant taste, and dry mouth (P-
value is  0.011). 
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This study is to assess oral signs, symptoms and oral lesions type 
and prevalence, in diabetic patients with End Stage Renal Disease (ESRD-
DM) and compare them with analogous findings in Non-End Stage Renal 
Disease (NESRD-DM) group. 
This study was conducted between June 2010 to May 2011 in the 
department of Oral Medicine and Radiology of Ragas Dental College and 
Hospital, and Voluntary Health Services, Adyar, Chennai 
The 200 Diabetic patients, who are diagnosed as having Non-End 
Stage Renal Disease (serum creatinine less than 2mg/dl) and End Stage 
Renal Disease undergoing dialysis will be taken up for the study. These 
patients will undergo general clinical examination to exclude HIV. The 
subjects were made to sit comfortably on a Dental Chair.  Sterile hand 
gloves were used during examination of the patients.  Patients were 
examined under halogen lamp in the dental chair under aseptic conditions 
and relevant demographic data were collected. Patients are examined for the 
presence of intra oral manifestations 
The study documents the following data: 
 In the present study, among the 200 subjects, 79 patients were male 
and 121 patients were female. Out of the 100 ESRD patients, 41 
patients (51.90%) are found to be male and 59 patients (48.80%) are 
found to be female .Among the 100 NESRD patients, 38 patients 
(48.10%) are male and 62 patients (51.20%) were female 
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 Among 200 patients, 72 were in age group of 12-40 years, 101 
patients were in age group of 41-60 years, 24 patients were in age 
group of 61-80 years, and 3 patients were in the age group of 81-100 
years. Among the 100 patients in ESRD- Diabetes Mellitus patients, 
22 (30.56%) were between 12-40yrs, 59 (58.41%) were between 41- 
60 yrs, 17 (70.83%) were between 61-80 yrs, 2 (66.67%) were 
between 81-100 yrs, Among the 100 patients in NESRD- Diabetes 
Mellitus patients, 50 (69.44%) were between 12- 40 yrs, 42 
(41.59%) were between 41-60 yrs, 7 (29.17%) were between 61-80 
yrs, 1 (33.33%) were between 81-100 yrs. 
 Among the 200 patients, 141 patients did not have any habits, 35 
patients have smoking habits, and 24 patients have tobacco related 
habits. Among 100 ESRD patients, 60 (42.60%) patients did not 
have any habits, 22 (62.90%) patients have smoking habits, and 18 
(75%) patients have tobacco related habits. Among 100 NESRD 
patients, 81 (57.40%) patients did not have any habits, 13 (37.10%) 
patients have smoking habits, and 6 (25%) patients have tobacco 
related habits. 
 Among the 200 patients, 106 patients were on renal diet, 91 patients 
were on vegetarian diet and 3 patients were on Non vegetarian diet. 
Among 100 ESRD patients, 29 patients (27.4%) were on renal diet, 
68 patients (74.70%) were on vegetarian diet and 3 (100%) patients 
were on Non vegetarian diet. Among 100 NESRD patients, 77 
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patients (72.6%) were on renal diet, 23 patients (25.30%) were on 
vegetarian diet and 0 (0%) patients were on Non vegetarian diet. 
 Among the 200 patients, 39 patients were IDDM (Insulin– 
Dependent Diabetes Mellitus) and 161 patients were NIDDM (Non 
Insulin – Dependent Diabetes Mellitus). Among 100 ESRD patients, 
17 (43.6%) were IDDM (Insulin – Dependent Diabetes Mellitus) 
patients and 83 (51.60%) were NIDDM (Non Insulin – Dependent 
Diabetes Mellitus) patients. Among 100 NESRD patients, 22 
(56.4%) were IDDM (Insulin – Dependent Diabetes Mellitus) 
patients and 78 (48.4%) were NIDDM (Non Insulin – Dependent 
Diabetes Mellitus) patients. 
 Among the 200 patients, 140 were found to be less than 12 yrs, 59 
were between 12-40yrs, 1 (100%) were between 40- 60 yrs, 0 (0%) 
were between 60-80 yrs. Among the 100 patients in ESRD- Diabetes 
Mellitus patients, 54 (38.58%) were found to be less than 12 yrs, 45 
(76.28%) were between 12-40yrs, 1 (100%) were between 40- 60 
yrs, 0 (0%) were between 60-80 yrs. Among the 100 patients in 
NESRD- Diabetes Mellitus patients, 86 (61.42%) were found to be 
less than 12 yrs, 14 (23.72%) were between 12- 40 yrs, 0 (0%) were 
between 40-60 yrs, 0 (0%) were between 60-80 yrs 
 Among the 200 patients, 46 patients had family history of Diabetes 
Mellitus and 154 patients did not have any family history of Diabetic 
Mellitus. Among 100 ESRD patients, 24 (52.2%) had family history 
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of Diabetes Mellitus and 76 (49.40%) patients did not have any 
family history of Diabetes Mellitus. Among 100 NESRD patients, 22 
(47.8%) had family history of Diabetes Mellitus and 78 (50.60%) 
patients did not have any family history of Diabetes Mellitus. 
 The fasting blood sugar level was found among the 200 patients, 71 
were found to be less than 120 mg/dl, 79 were between 120-200 
mg/dl, and 50 were more than 200 mg/dl. Among the 100 patients in 
ESRD- Diabetes Mellitus patients, 30 (42.25%) were found to be 
less than 120 mg/dl, 42 (53.17%) were between 120-200 mg/dl, 28 
(56%) were more than 200 mg/dl. Among the 100 patients in 
NESRD- Diabetes Mellitus patients, 41 (57.75%) were found to be 
less than 120 mg/dl, 37 (46.83%) were between 120-200 mg/dl, 22 
(44%) were more than 200 mg/dl, 
 Among the 200 patients, 40 patients were hypertensive and 160 
patients were normotensive. Among 100 ESRD patients, 26 (65%) 
were hypertensive patients and 74 (46.30%) were normotensive. 
Among 100 NESRD patients, 14 (35%) were hypertensive patients 
and 86 (53.70%) were normotensive 
 The hemoglobin level was found among the 200 patients, 63 were 
found to be less than 10 mg/dl, 128 were between 10-15 mg/dl, 9 
were more than 15 mg/dl.Among the 100 patients in ESRD- 
Diabetes Mellitus patients, 56 (88.89%) were found to be less than 
10 mg/dl, 41 (32.03%) were between 10-15 mg/dl, 3 (33.33%) were 
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more than 15 mg/dl. Among the 100 patients in NESRD- Diabetes 
Mellitus patients, 7 (11.11%) were found to be less than 10 mg/dl, 
87 (67.97%) were between 10-15 mg/dl, 6 (66.67%) were more than 
15 mg/dl. 
 The Serum Creatinine level was found among the 200 patients, 100 
were found to be less than 2 mg/dl, 91 were between 2-10 mg/dl, 9 
were more than 10 mg/dl. Among the 100 patients in ESRD- 
Diabetes Mellitus patients, 0 (0%) were found to be less than 2 
mg/dl, 91 (100%) were between 2-10 mg/dl, 9 (100%) were more 
than 10 mg/dl. Among the 100 patients in NESRD - Diabetes 
Mellitus patients, 100 (100%) were found to be less than 2 mg/dl, 
(0%) were between 2-10 mg/dl, 0 (0%) were more than 10 mg/dl. 
 The blood urea level was found among the 200 patients, 137 were 
found to be less than 50 mg/dl, 40 were between 50-100 mg/dl, 23 
(100%) were more than 100 mg/dl. Among the 100 patients in 
ESRD- Diabetes Mellitus patients, 37 (27%) were found to be less 
than 50 mg/dl, 40 (100%) were between 50-100 mg/dl, 23 (100%) 
were more than 100 mg/dl. Among the 100 patients in NESRD- 
Diabetes Mellitus patients, 100 (73%) were found to be less than 50 
mg/dl, 0 (0%) were between 50-100 mg/dl, 0 (0%) were more than 
100 mg/dl. 
 Among 200 subjects, 58 patients had taken metformin, 95 patients 
had taken sulphonyl urea and 47 patients had taken insulin. Out of 
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the 100 ESRD patients, 52 patients (89.70%) had taken metformin, 
40 (42.10%) patients had taken sulphonyl urea and 8 (17%) patients 
had taken insulin. Among 100 NESRD patients, 6 patients (10.30%) 
had taken metformin, 55 (57.90%) patients had taken sulphonyl urea 
and 39 (83%) patients had taken insulin, 
 Among the 200 patients, 24 patients had Saburral Tongue (p value ≤ 
0.002), 4 patients had Fissured Tongue(p value ≤ 1.000), 18 patients 
had smooth Tongue (P value ≥ 0.323), 23 patients had burning 
Tongue (P value ≥ 0.506), 51 patients had Candidiasis (P value ≥ 
0.417), 44 patients had Dry and Fissured Lips (P value ≥ 1.000), 20 
patients had Petechiae / Ecchymoses (P value ≤ 0.000), 13 patients 
had Angular Chelitis (P value ≥ 0.152) , 1 patients had Uremic 
Stomatitis (P value ≥ 0.316), 53 patients had Uremic Fetor (P value 
≤ 0.000), 82 patients had Xerostomia (P value ≥ 0.774), 8 patients 
had Herpes Labialis (P value ≥ 0.470), 5 patients had Aphthous 
Ulcer (P value ≥ 0.174), 59 patients had Pale Mucosa (P value ≤ 
0.000), 86 patients had Unpleasant Taste (P value ≥ 0.391), 4 
patients had Stomatitis Medicamentosa (P value ≤ 0.043), 11 
patients had Lichen Planus (P value ≥ 0.352).  Among 100 ESRD 
patients, 19 (79.20%) had Saburral Tongue, 2 (50%) had Fissured 
Tongue, 11 (61.10%) had smooth Tongue, 13 (56.50%) had Burning 
Tongue, , 23 (45.10%) had Candidiasis, 22 (50.00%) had Dry and 
Fissured Lips, 18 (90.00%) had Petechiae / Ecchymoses, 4 (30.80%) 
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had Angular Chelitis, , 1(100%) patients had Uremic Stomatitis, 52 
(98.10%) had Uremic Fetor, 42 (51.20%) had Xerostomia 5 
(62.50%) had Herpes Labialis, 1 (20%) had Aphthous Ulcer, 45 
(76.30%) had Pale Mucosa, 46 (53.50%) had Unpleasant Taste, 4 
(100%) had Stomatitis Medicamentosa, 7 (63.60%) had Lichen 
Planus. Among 100 NESRD patients, 5 (20.80%) had Saburral 
Tongue, 2 (50%) had Fissured Tongue, 7 (38.90%) had smooth 
Tongue, 10 (43.50%) had Burning Tongue, 28 (54.90%) had 
Candidiasis, 22 (50.00%) had Dry and Fissured Lips, 2 (10.00%) had 
Petechiae / Ecchymoses, 9 (69.20%) had Angular Chelitis, 0 (0%) 
patients had Uremic Stomatitis  , 1 (1.90%) had Uremic Fetor, 40 
(48.80%) had Xerostomia, 3 (37.50%) had Herpes Labialis, 4 (80%) 
had Aphthous Ulcer, 14 (23.70%) had Pale Mucosa, 40 (46.50%) 
had Unpleasant Taste , ), 0 (0%)  had Stomatitis Medicamentosa 4 
(36.40%) had Lichen Planus.   
In conclusion of the study it is to be pointed out that ESRD-DM 
patients had a significantly higher prevalence of signs, symptoms and oral 
lesions, as compared to non-ESRD DM patients. This observation agrees 
with previous reports of ESRD predisposing to oral manifestations in the 
diabetic patient. Oral manifestations were, moreover, barely symptomatic 
when present, or were probably less of a trouble for the patient as compared 
to other manifestations of ESRD. Those frequently found conditions of 
uremic fetor, unpleasant taste, xerostomia, pale mucosa, burning tongue, 
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dry- fissured lips, candidiasis, saburral tongue or smooth tongue in our study 
group, could be tried as warning signs for undiagnosed kidney disease in 
other diabetic patients. The diagnosis and treatment of oral lesions will 
contribute to improve the quality of life of the ESRD-DM patient 
                                                                                                                                                          
Bibliography 
 
   
 
144 
1. National Kidney Foundation. K/DOQI clinical practice guidelines for 
chronic kidney disease: evaluation, classification, and stratification. Am 
J Kidney Dis 2002; 39: S1–266.  
2. Feest TG, Rajamahesh J and Byrne C, Trends in adult renal replacement 
therapy in the UK: 1982- 2002. QJM 2005; 98: 21-28 
3. Löe H, Periodontal disease: the sixth complication of diabetes mellitus. 
Diabetes Care 1993; 16(1):329-334. 
4. Taylor GW and Borgnakke WS, Periodontal disease: associations with 
diabetes, glycemic control and complications. Oral Dis 2008; 14(3): 
191-203. 
5. Ship JA., Diabetes and Oral Health: an overview. JADA 2003; 
134(suppl):4S-10S. 
6. Collins, V. R., Dowse, G. K., Finch, C. F., Zimmet, P. Z. and Linnanae, 
A. W. Prevalence and risk factors for micro- and macroalbuminuria in 
diabetic subjects and entire population of Nauru.1989, Diabetes 38, 
1602-1610 
7. King, H., Aubert, R. and Herman, W., Diabetes mellitus, Diabetes Care 
1998; 21, 1414–1431. 
8. Mallick NP and Gokal ,. Haemodialysis., Lancet 1999; 353: 737-742 
9. Oldenburg B, MacDonald GJ and Perkins RJ, Factors influencing 
excessive thirst and fluid intake in dialysis patients. Dial Transplant 
1988; 17: 21-23 
                                                                                                                                                          
Bibliography 
 
   
 
145 
10. Everett KD, Brantley PJ, Sletten C, Jones GN and McKnight GT, The 
relation of stress and depression to interdialytic weight gain in 
haemodialysis patients. Behav Med 1995; 21: 25-30 
11. Leggat JE, Jr., Orzol SM and Hulbert-Shearon TE , Noncompliance in 
hemodialysis: predictors and survival analysis. Am J Kidney Dis 1998; 
32: 139-145 
12. Moran PJ, Christensen AJ and Lawton WJ, Social support and 
consciousness in hemodialysis adherence. Ann Behav Med 1997; 19: 
333-338 
13. Fliser D and Haller H, Nephropathie bei Diabetes mellitus Type 2 
(Nephropathy in Type 2 DM). Der Internist 2000; 41: 1363 – 73. 
14. Stephen Pastan, M.D., and James Bailey, M.D, Dialysis Therapy, N 
Engl J Med 1998; 338:1428-1437 
15. Belmiro Cavalcanti do Egito Vasconcelos , Moacir Novaes , Francisco 
Aurelio Lucchesi Sandrini , Almir Walter de Albuquerque Maranhão 
Filho and Leila Santana Coimbra , Prevalence of oral mucosa lesions in 
diabetic patients: a preliminary study Rev Bras Otorrinolaringol 
2008;74(3):423-8. 
16. Antunes FS, Graça MA, and Nurkim NL,. Periodontal disease and 
diabetes mellitus.. Rev Odonto Cienc 2003; 18(40):107-111.  
17. Rivera EJ,. Insulin and insulin-like growth factor expression and 
function deteriorate with progression of Alzheimer’s disease:link to 
brain in acetylcholine. J Alzheimers Dis 2005;8(3):247-268.  
                                                                                                                                                          
Bibliography 
 
   
 
146 
18. Paradella TC, Monteiro da Silva CM, and Arisawa EA, O Que o 
Cirurgião-Dentista Deve Saber Sobre o Paciente Diabético Tipo I,. Rev 
EAP / APCD 2001;1(3):12-7.  
19. Kitabchi AE, Umpierrez GE, Murphy MB, and Kreisberg RA 
(December 2006)."Hyperglycemic crises in adult patients with diabetes: 
a consensus statement from the American Diabetes Association". 
Diabetes Care 29 (12): 2739–48. 
20. Burkits, Textbook Of Oral Medicine, 10thedition, 2003, pg 563 – 57521. 
21. Scherer LP, and Lobo FMB., Pesquisa do nistagmo / vertigem de 
posição e avaliação eletronistagmográfica em um grupo de indivíduos 
portadores de diabetes Mellitus tipo I, Rev Bras Otorrinolaringol 
2002;68(3):355-36024. 
22. Maia CAS, and Campos CAH, Diabetes Mellitus como causa de perda 
auditiva., Rev Bras Otorrinolaringol 2005;71(2):208-214.  
23. Tommasi AF. Diagnóstico em patologia bucal. 2ª ed. São Paulo, Brasil: 
Editora Pancast; 1997. p. 527-558. 
24. Moore PA, Guggenheimer J, Etzel KR, Weyant RJ, and  Trevor O: Type 
1 diabetes mellitus, xerostomia, and salivary flow rates. Oral Surg Oral 
Med Oral Pathol Oral Radiol Endod 2001, 92:281-91. 
25. Guggenheimer J, Moore PA, and Rossie K, Insulin-dependent diabetes 
mellitus and oral soft tissue pathologies, II: prevalence and 
characteristics of Candida and Candidal lesions. Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod 2000; 89(5):570-576 
                                                                                                                                                          
Bibliography 
 
   
 
147 
26. Sousa RR, Castro RD, and Monteiro CH , O Paciente Odontológico 
Portador de Diabetes Mellitus: Uma Revisão de Literatura. Pesq Bras 
Odontoped Clin Integr 2003;3(2):71-77. 
27. Yuli M, Muller A, and Yuraima P., Manifestaciones bucales de la 
Diabetes Mellitus Gestacional- Presentación de dos casos y revision de 
la literatura. Acta Odontol Venez 2002; 40(2):160-164. 
28. Belmiro Cavalcanti do Egito Vasconcelos , Moacir Novaes , Francisco 
Aurelio Lucchesi Sandrini , Almir Walter de Albuquerque Maranhão 
Filho ,and  Leila Santana Coimbra ,Prevalence of oral mucosa lesions in 
diabetic patients: a preliminary study Rev Bras Otorrinolaringol 
2008;74(3):423-8. 
29. Jawa A, Kcomt J, and Fonseca VA. Diabetic nephropathy and 
retinopathy. Med Clin N Am 2004; 88: 1001 – 1036. 
30. Mogensen CE. Progression of nephropathy in long-term diabetics with 
proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin 
Lab Invest 1976; 36: 383 – 388. 
31. Parving HH, Smidt UM, and Friisberg B, A prospective study of 
glomerular filtration rate and arterial blood pressure in insulin-dependent 
diabetics with diabetic nephropathy. Diabetologia 1981; 20: 457 – 461. 
32. Cooper ME, Gilbert RE, and Epstein M. Pathophysiology of diabetic 
nephropathy.  Metabolism 1998; 47 (Suppl 1): 3 – 6. 
33. Cooper ME. Pathogenesis, prevention, and treatment of diabetic 
nephropathy.  Lancet 1998; 352: 213 – 219. 
                                                                                                                                                          
Bibliography 
 
   
 
148 
34. Gonzalez-Albarran O, Gomez, Ruiz E, Vieitez P, and Garcia-Robles R. 
Role of Systolic blood pressure on the progression of kidney damage in 
an experimental model of type 2 diabetes mellitus, obesity, and 
hypertension (Zucker Rats). AJH 2003; 16: 979 – 985. 
35. Barnett A. Prevention of loss of renal function over time in patients with 
diabetic nephropathy. The American Journal of Medicine 2006; 119: 
40S – 47S. 
36. Kroustrup JP, Gundersen HJ, and Osterby R. Glomerular size and 
structure in diabetes mellitus. III. Early enlargement of the capillary 
surface. Diabetologia 1977; 13: 207 – 10. 
37. Hostetter TH, Rennke HG, and Brenner BM. The case for intrarenal 
hypertension in the initiation and progression of diabetic and other 
glomerulopathies. Am J Med 1982; 72: 375 – 80. 
38. Held PJ, The United States Renal Data System’s 1991 annual data 
report: an introduction. Am J Kidney Dis 1991; 18:1-16. 
39. Makino H, Phenotypic modulation of the mesangium reflected by 
contractile proteins in diabetes. Diabetes 1996; 45:488-95. 
40. Peter J Watkins, ABC of Diabetes, 5th Edition, 2003, pg no: 65-66. 
41. Nielsen S, The clinical course of renal function in NIDDM patients with 
normal and microalbuminuria. J Intern Med 1997; 241:133-141. 
42. Raile K, Diabetic nephropathy in 27,805 children, adolescents, and 
adults with type 1 diabetes: effect of diabetes duration, HBA1c, 
                                                                                                                                                          
Bibliography 
 
   
 
149 
hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007; 
30:2523-2528. 
43. Remuzzi G, Clinical practice. Nephropathy in patients with type 2 
diabetes. N Engl J Med 2002; 346:1145-1151. 
44. Steinke JM, The early natural history of nephropathy in type 1 diabetes: 
III. Predictors of 5-year urinary albumin excretion rate patterns in 
initially normo-albuminuric patients. Diabetes 2005; 54:2164-2171. 
45. Evans N, and Forsyth E. End-stage renal disease in people with type 2 
diabetes: systemic manifestations and exercise implications. Phys Ther. 
2004;84:454–463 
46. Alba Jover Cerveró, José V. Bagán, Yolanda Jiménez Soriano, and 
Rafael Poveda Roda, Dental management in renal failure: Patients on 
dialysis, Med Oral Patol Oral Cir Bucal. 2008 Jul 1;13(7):E419-426. 
47. Andrew S. Levey, Juan P. Bosch, and Julia Breyer Lewis, Tom Greene, 
Nancy Rogers, and David Roth, A More Accurate Method To Estimate 
Glomerular Filtration Rate from Serum Creatinine: A New Prediction 
Equation Ann Intern Med. 1999;130:461-470 
48. Antonio Nicolucci1, Sheldon Greenfield And Soeren Mattke, Selecting 
indicators for the quality of diabetes care at the health systems level in 
OECD countries International Journal for Quality in Health Care; 
September 2006: pp. 26–30 
                                                                                                                                                          
Bibliography 
 
   
 
150 
49. Eleanor Lederer, MD, and Rosemary Ouseph, Chronic Kidney Disease 
American Journal of Kidney Diseases, Vol 49, No 1 (January), 2007: pp 
162-171 
50. Chih-Cheng Hsu, Shang-Jyh Hwang, Chi-Pang Wen, , Hsing-Yi Chang, 
Ted Chen, , Ruei-Shiang Shiu, Shiow-Shiun Horng, Yu-Kang Chang 
and Wu-Chang Yang, High Prevalence and Low Awareness of CKD in 
Taiwan: A Study on the Relationship Between Serum Creatinine and 
Awareness From a Nationally Representative Survey,  American Journal 
of Kidney Diseases Volume 48, Issue 5, November 2006, Pages 727-738  
51. Sanjay Kumar Agarwal1, Suresh Chand Dash1, Mohammad Irshad2, 
Sreebhuasn Raju1,  Ravinder Singh1 and Ravinder Mohan Pandey, 
Prevalence of chronic renal failure in adults in Delhi, India Nephrol Dial 
Transplant (2005) 20: 1638–1642 
52. Jean-Franc¸ and ois Yale, Oral Antihyperglycemic Agents and Renal 
Disease: New Agents, New Concepts J Am Soc Nephrol 16: S7–S10, 
2005. 
53. De Rossi SS, and Glick M. Dental considerations for the patient with 
renal disease receiving hemodialysis. J Am Dent Assoc, 1996; 127:211-
219. 
54. Jover Cerveró A, Bagán JV, Jiménez Soriano Y, and Poveda Roda R., 
Dental management in renal failure: patients on dialysis. Med Oral Patol 
Oral Cir Bucal. 2008;13:419-26. 
                                                                                                                                                          
Bibliography 
 
   
 
151 
55. Proctor R, Kumar N, Stein A, Moles D, and Porter S., Oral and dental 
aspects of chronic renal failure. J Dent Res. 2005;84:199-208. 
56. Davidovich E, Davidovits M, Eidelman E, Schwarz Z, and Bimstein E.  
Pathophysiology, therapy, and oral implications of renal failure in 
children and adolescents: an update. Pediatr Dent. 2005;27:98-106. 
57. Kerr AR, Update on renal disease for the dental practitioner. Oral Surg 
Oral Med Oral Pathol Oral Radiol Endod. 2001;92:9-16. 
58. Sharma DC, and Pradeep AR, End stage renal disease and its dental 
management. N Y State Dent J. 2007; 73:43-7. 
59. Eugene Sobngwi, Sostanie Enoru, Gloria Ashuntantang, Marcel Azabji-
Kenfack, Mesmin Dehayem, Arnold Onana, Daniel Biwole, Franc¸ Ois 
Kaze, Jean-Franc¸ Ois Gautier, and Jean-Claude Mbanya, Day-to-Day 
Variation of Insulin Requirements of Patients With Type 2 Diabetes and 
End-Stage Renal Disease Undergoing Maintenance Hemodialysis, 
Diabetes Care 33:1409–1412, 2010 
60. James McKiernan, Rachel Simmons, Jared Katz and Paul Russo, Natural 
history of chronic renal insufficiency after partial and radical 
nephrectomy , Urology  Volume 59, Issue 6, June 2002, Pages 816-820 
61. Burkits, Textbook Of Oral Medicine, 10thedition, 2003, pg 426 
62. Miller CS, Little JW, and Falace DA. Supplemental corticosteroids for 
dental patients with adrenal insufficiency: reconsideration of the 
problem.  J Am Dent Assoc. 2001;132:1570-9. 
                                                                                                                                                          
Bibliography 
 
   
 
152 
63. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson 
JL, Harrison´s Principles of Internal Medicine. New York: McGraw-
Hill; 2005.16th edition pg. 1653-63. 
64. Robert N. Foley and Allan J. Collins, End-Stage Renal Disease in the 
United States: An Update from the United States Renal Data System J 
Am Soc Nephrol 18: 2644–2648, 2007 
65. Amato D, Alvarez AC, Castañeda LR, Rodríguez E, Avila DM, and 
Arreola F, Prevalence of chronic kidney disease in an urban Mexican 
population. Kidney Int 2005;68:S11-7. 
66. De La Rosa-García E, Mondragón-Padilla A, Aranda-Romo S, and  
Bustamante-Ramírez MA. Oral mucosa symptoms, signs and lesions, in 
end stage renal disease and non-end stage renal disease diabetic patients. 
Med Oral Patol Oral Cir Bucal 2006;11:E467-73. 
67. Chi-yuan Hsu, Eric Vittinghoff, Feng Lin, and Michael G. Shlipak, The 
Incidence of End-Stage Renal Disease Is Increasing Faster than the 
Prevalence of Chronic Renal Insufficiency Ann Intern Med. 
2004;141:95-101. 
68. Emmanuel Villar, Stephen Peter Mcdonald, and Cécile Couchoud, 
Incidence of Treatment for End-Stage Renal Disease among Individuals 
with Diabetes in the U.S.  Continues to Decline Diabetes Care, Volume 
33, Number 5, May 2010 :65-69. 
                                                                                                                                                          
Bibliography 
 
   
 
153 
69. Zohreh Hajheydari, and Atieh Makhlough, Cutaneous and Mucosal 
Manifestations in Patients on Maintenance Hemodialysis A Study of 101 
Patients in Sari, Iran, Iranian Journal of Kidney Diseases ,2008;2:86-90. 
70. Franois madore, Edmund Lowrie, Carlo Brugnara, Nancy Lew, j. 
Michael lazarus, Kenneth bridges and William F. Owen, Anemia in 
Hemodialysis Patients: Variables Affecting this Outcome Predictor, J 
Am Soc Nephrol 8, 1997:1921-1929. 
71. Gall M-A, Hougaard P, and Borch-Johnsen K, Risk factors for 
development of incipient and overt diabetic nephropathy in patients with 
noninsulin- dependent diabetes mellitus: prospective observational 
study. BMJ. 1997;314:783-788. 
72. Choy BY, Ho YW, Chau KF, Leung CB, Tsang WK, and Lui SF. Renal 
replacement therapy for patients with diabetes mellitus in Hong Kong. 
Hong Kong Journal of Nephrology 2001; 3: 89 – 96. 
73. Olugbenga. E. Ayodele , C. Olutayo Alebiosu, and Babatunde. L. 
Salako, Diabetic Nephropathy A Review of the Natural History, Burden, 
Risk Factors and Treatment Journal Of The National Medical 
Association Vol. 96, NO. 11, November 2004 1445-1454. 
74. Jorge l. Gross, Mirela j. De azevedo, Sandra p. Silveiro, Lu´is henrique 
canani, Maria luiza caramori, and Themis zelmanovitz, Diabetic 
Nephropathy: Diagnosis, Prevention, and Treatment ,Diabetes Care 
2005,28:176–188.  
                                                                                                                                                          
Bibliography 
 
   
 
154 
75. Thorman R, Neovius M, and Hylander B, Prevalence and early detection 
of oral fungal infection: a cross-sectional controlled study in a group of 
Swedish end-stage renal disease patient,. Scand J Urol Nephrol. 2009; 
43(4):325-330. 
76. Gábor L. Kovács, Diabetic Nephropathy - eJIFCC , 2009,pg-40-52 
77. Britt B. Newsome, David G. Warnock, William M. McClellan, Charles 
A. Herzog, Catarina I. Kiefe, Paul W. Eggers, and Jeroan J. Allison, 
Long-term Risk of Mortality and End-Stage Renal Disease Among the 
Elderly After Small Increases in Serum Creatinine Level During 
Hospitalization for Acute Myocardial Infarction, Arch Intern Med. 
2008;168(6):609-616 
78. Ritz E, Bergis K, Strojek K, and Keller C., Nephropathy and 
hypertension in type II diabetes, Med Klin (Munich). 1997 Jul 
15;92(7):421-425. 
79. Barry I. Freedman, J. Michael Soucie, and William M. Mcclellan, 
Family History of End-Stage Renal Disease among Incident Dialysis 
Patients, J Am Soc Nephrol 1997 ,8: 1942-1945,  
80. Udayakumar P, Balasubramanian S, Ramalingam KS, Lakshmi C, 
Srinivas CR, and Mathew AC. Cutaneous manifestations in patients with 
chronic renal failure (CRF) on hemodialysis. Indian J Dermatol 
Venereol Leprol 2006;72:119-25 
81. Shu-Fen Chuang, Junne-Ming Sung, Shih-Chen Kuo, Jeng-Jong Huang, 
and Su-Yuan Lee, Oral and dental manifestations in diabetic and 
                                                                                                                                                          
Bibliography 
 
   
 
155 
nondiabetic uremic patients receiving hemodialysis, Oral Surg Oral Med 
Oral Pathol Oral Radiol Endod 2005;99:689-95 
82. P. Mosannen Mozaffari, Amirchaghmaghi, and  Mortazavi, Oral 
Manifestations of Renal Patients Before and After Transplantation: A 
Review of Literature ,DJH 2009; Vol.1, No.1,pg 1-6 
83. A M El Nahas, A Masters-Thomas, S A Brady, K Farrington, V 
Wilkinson,  Z Varghese, and J F Moorhead, Selective effect of low 
protein diets in chronic renal diseases British Medical Journal Volume 
289 17 November 1984, pg 1337-1341 
84. Agarwal SK, Dash SC, and Irshad M, Prevalence of chronic renal failure 
in adults in Delhi, India. Nephrol Dial Transplant.2005;20:1638–1642. 
85. Robert N. Foley and Allan J. Collins, End-Stage Renal Disease in the 
United States: An Update from the United States Renal Data System ,  J 
Am Soc Nephrol 18: 2644–2648, 2007 
86. Sowell SB, Dental care for patients with renal failure and renal 
transplants. JADA 1982;104:171-7. 
87. Carl W, and Wood RH. The dental patient with chronic renal failure. 
Quintessence Int1976;7:9-15. 
88. Hovinga J, Roodvoets AP, and Gaillard J.  Some findings in patients 
with uremic stomatitis.  J Maxillofac Surg 1975; 3:125-7.  
89. Vesterinen M, Ruokonen H, Furuholm J, Honkanen E, and Meurman 
JH., Clinical questionnaire study of oral health care and symptoms in 
                                                                                                                                                          
Bibliography 
 
   
 
156 
diabetic vs. non-diabetic predialysis chronic kidney disease patients. 
Clin Oral Investig. 2011 Apr 1:453-45994 
90. Gavaldá C, Bagán JV, Scully C, Silvestre FJ, Milián MA, and  Jiménez, 
Renal hemodialysis patients: oral, salivary, dental and periodontal 
findings in 105 adult cases. Oral Dis 1999;5:299-302 
91. De La Rosa-García E, Mondragón-Padilla A, Irigoyen-Camacho ME, 
and Bustamante-Ramírez MA. Oral lesions in a group of kidney 
transplant patients. Med Oral Patol Oral Cir Bucal 2005;10:196-204. 
92. Safia A. Al-Attas, and  Soliman O. Amro, Candidal colonization, strain 
diversity, and antifungal susceptibility among adult diabetic patients, 
Ann Saudi Med 2010; 30(2): 101-108 
93. E. de la Rosa García, S. Cruz Mérida and A. Mondragón Padilla, Tooth 
loss in diabetic patients with and without end-stage renal disease and 
dialysis Nefrología 2008; 28 (6) 645-648 
94. Abe M, Okada K and Soma M., Antidiabetic agents in patients with 
chronic kidney disease and end-stage renal disease on dialysis: 
metabolism and clinical practice, Curr Drug Metab. 2011 Jan; 12(1):57 
95. Jean-Francoise Yale, Oral Antihyperglycemic Agents and Renal 
Disease: New Agents, New Concepts  J Am Soc Nephrol 2005,16: S7–
S10,  
96. M. Greenwood and J. G. Meechan, General medicine and surgery for 
dental practitioners Part 6: The endocrine system British Dental Journal 
2003; 195: pg 129–133 
                                                                                                                                                          
Bibliography 
 
   
 
157 
97. Janelle C Nisbet, Joanna M Sturtevant, and   Johannes B Prins, 
Metformin and serious adverse effects, MJA Vol 180 19 January 2004, 
Pg- 53-54 
98. Devasmita Choudhury and Cynthia Luna-Salazar,  Preventive health 
care in chronic kidney disease and end-stage renal disease, nature 
clinical practice april 2008 vol  no 4, pg 194-206 
99. Farman A.G, Central papillary atrophy of the tongue; Oral Surg. 1977: 
43: Pg 48-58. 
100. Arendorf TM and DM Walker: Oral Candidal population in Health 
and disease. Br Dent J, 1979: 147: 267-272. 
101. Jay D. Shulman, and Francisco Rivera-Hidalgo, The prevalence of   
oral mucosal lesions in U.S. adults J Am Dent Assoc, 2004 Vol 135, No 
9, 1279-1286.  
102. Prabhu SR, Wilson DF, Daftary DK and Johnson NW. Oral diseases 
in tropics. 1
st
 edition, 1993 25-125. 
103. Ronald D. Perrone, Nicolaos E. Madias, and Andrew S. Levey, 
Serum Creatinine as an Index of Renal Function: New Insights into Old 
Concepts, CLIN.CHEM.38/10, 1933-1953 (1992) 
104. Jean-Luc Orsonneau, Catherine Massoubre, Marie Cabanes, and 
Patrick Lustenberger, Simple and Sensitive Determination of Urea in 
Serum and Urine, CLIN.CHEM.38/5,619-623(1992) 
105. Anjan basak, Development Of A Rapid And Inexpensive Plasma 
Glucose Estimation By Two-Point Kinetic Method Based On Glucose 
                                                                                                                                                          
Bibliography 
 
   
 
158 
Oxidase-Peroxidase Enzymes, Indian Journal Of Clinical Biochemistry, 
2007 / 22 (1) 156-160 
106. Hans Berninger and Roger Smith, A Modification of the 
Spectrophotometric Determination of Carbon Monoxide in Blood 
Enabling Direct Determination of Per Cent Hemoglobin Saturation, 
Clinical Chemistry Vol. 5, No. 2, 1959, 127-134. 
107. Borch-Johnsen K, Andersen PK, Deckert T. The effect of proteinuria 
on relative mortality in type 1 (insulin-dependent) diabetes mellitus. 
Diabetologia 1985;28(8):590-6. 
108. Groop PH, Thomas MC, Moran JL, Wadén J, Thorn LM, Mäkinen 
VP, et al. The presence and severity of chronic kidney disease predicts 
all-cause mortality in type 1 diabetes. Diabetes 2009; Jul; 58(7):1651-8. 
 
 
 
 
Annexure I 
 
159 
 
Master chart of ESRD -DM Patients 
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3 27 F   NV     1 12     1   12 126 124 4.8             1   1     1 1 1     1 
4 25 F   NV   1   10     1   4.8 220 81 6.2             1           1       1 
5 49 F   R 1   1 20     1   6.3 99 90 4.6     1                 1 1 1       
6 58 M T NV     1 20     1   2.6 148 42 5.4                                   
7 55 M T NV 1   1 15   1     7.1 120 110 9.8                       1 1 1       
8 60 F   NV     1 15 1   1 1 2.8 144 47 7.7                       1 1 1       
9 31 F   NV   1   17     1   2.2 170 43 8.8         1             1   1     1 
10 61 F   NV     1 20   1     3 132 45 7.4 1       1               1 1     1 
11 38 M S NV     1 10   1     2.3 154 48 5.7         1             1 1 1     1 
12 45 F   V 1   1 20     1   12 160 180 7.3                       1 1 1     1 
13 47 M S NV 1   1 2   1     12 96 122 9.9                   1   1 1 1 1   1 
14 39 M S NV     1 6   1     5.8 75 93 11 1                     1 1       1 
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15 55 M S R 1   1 30   1     11 142 155 16 1             1       1 1   1     
16 46 M S NV     1 20   1     2.5 206 45 8.8           1               1 1     
17 18 M   NV 1 1   15     1   6.7 197 87 8.5       1                   1       
18 46 F   V 1   1 10 1 1     4.4 185 96 8                                   
19 50 M S NV 1   1 30 1 1     11 270 162 7.2 1   1                 1 1 1       
20 45 F   NV 1   1 30 1 1     5.6 210 110 8.8     1     1               1     1 
21 46 F   NV 1 1   30     1   8.2 240 74 7.8       1     1       1 1 1 1     1 
22 55 F   NV     1 10   1     7.4 180 52 8.9                           1   1   
23 43 M t NV 1   1 10   1     15 96 150 4.9   1   1     1             1     1 
24 68 F   NV 1   1 2     1   3 111 67 8.9       1               1 1 1     1 
25 72 F t NV     1 10   1     2.8 170 122 13                       1           
26 30 F t NV     1 16     1   2.8 84 123 8                 1     1       1 1 
27 65 M s V     1 15 1 1     2.9 190 54 13       1   1           1 1         
28 48 F   V     1 15 1 1     2.4 71 76 13       1 1             1         1 
29 61 F t V     1 10   1     4.8 117 49 7.9       1               1         1 
30 55 F   V     1 15 1   1   4 202 50 9.9     1                           1 
31 56 M s V     1 19 1 1     3.1 125 60 8.9 1     1               1 1         
32 47 M s V     1 5 1 1     3 210 65 10                                   
33 60 M s NV     1 25 1 1     3.4 125 66 7.6 1         1 1         1 1         
34 60 M   V     1 8   1     4.8 190 111 11                       1           
35 47 F   NV     1 20       1 2.4 337 40 11                                   
36 65 M s V     1 20 1 1     3.6 142 60 13                       1           
37 58 F   NV     1 20     1   3.4 110 45 12                     1 1 1         
38 60 F t V 1   1 11 1 1     2.5 137 111 11                       1           
39 30 M   NV   1   19 1   1   4.2 203 123 12 1   1                             
40 66 F t NV     1 10   1     5.2 120 40 9.7 1                     1           
41 58 F t NV     1 30   1     4.9 184 48 10 1               1       1         
42 70 M t V 1   1 20       1 3.2 186 48 11         1                         
43 60 F   NV     1 2   1     5.2 140 40 12           1           1 1         
44 45 M t V     1 4   1     3.3 188 77 14       1                   1       
45 60 F t V     1 40     1   3.3 198 142 16         1                 1     1 
46 85 F   V 1   1 2   1     3.7 93 42 12     1 1               1   1       
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47 50 M   V     1 9   1     3.7 164 48 7.9     1                 1 1       1 
48 42 M s NV     1 5   1     4.5 223 65 8.2     1                     1     1 
49 36 F   NV   1   26     1   2.2 82 111 10     1     1               1     1 
50 55 F   NV 1   1 10 1   1   2.8 300 76 12 1 1 1 1 1             1   1     1 
51 38 M   NV     1 8   1     3.1 214 48 9.4     1                   1 1     1 
52 60 F   NV     1 10     1   2.3 86 40 7     1     1               1       
53 53 F   NV     1 5 1 1     2.8 200 77 8.5 1                     1 1 1       
54 60 M s NV     1 30 1 1     3.1 210 40 12 1   1   1                 1     1 
55 55 F   NV     1 5       1 4 91 76 12     1                 1   1       
56 40 M   NV     1 25 1 1     2.2 160 76 11                       1       1   
57 55 F   NV     1 2     1   4 242 40 11 1                     1 1       1 
58 43 F   NV     1 3   1     2.4 210 35 12                       1 1         
59 60 M s NV 1   1 40     1   2.8 80 76 13 1                     1         1 
60 48 F   V     1 5     1   4.7 210 115 13       1 1   1         1 1     1   
61 46 F   NV     1 5     1   3.1 93 132 13       1               1           
62 47 f   NV   1   22     1   4 221 123 11 1           1         1 1         
63 17 F   NV   1   10     1   2.7 108 69 12                                   
64 38 F   NV   1   10       1 3.9 152 133 12         1 1                     1 
65 28 M s V     1 12     1   4 183 76 8                       1         1 
66 51 M s NV     1 10     1   4.2 84 67 9.8 1           1   1       1       1 
67 41 M t NV 1 1   20 1   1   2.1 134 43 9.8     1   1   1           1       1 
68 65 F t NV 1   1 15   1     4.4 294 52 9.9 1   1                 1 1       1 
69 59 M s NV     1 15     1   4.7 101 67 7.9     1   1           1 1           
70 39 F   NV   1   35 1   1   2.6 157 56 12       1 1             1 1 1     1 
71 21 F   V   1   15     1   2.3 204 55 9     1                     1     1 
72 61 F   V     1 48   1     11 92 123 8.6           1                   1 1 
73 47 M t V     1 22 1 1     13 116 132 7.6             1         1   1 1   1 
74 53 F   NV     1 8 1   1   4.7 239 98 8.8                           1     1 
75 65 F t NV 1   1 10   1     4.2 108 40 13       1 1                 1       
76 81 M   NV 1   1 5   1     2.4 265 44 13     1   1                 1     1 
77 79 M s NV     1 4   1     3.8 125 69 13           1                   1   
78 71 F   NV 1   1 21   1     4.2 86 47 8.5                           1       
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79 62 F   V     1 8   1     2.9 215 44 14       1                           
80 52 F   V     1 15     1   4.5 243 55 11                       1   1       
81 36 M   V   1   25     1   2.5 150 53 13                           1   1   
82 37 M   NV     1 11   1     3 82 66 16         1       1     1   1       
83 61 M s NV     1 8     1   3.5 151 40 12     1                 1 1         
84 64 F   V     1 31     1   2.9 119 45 13                           1       
85 59 F   V 1   1 6 1   1   3.9 135 42 10                       1 1 1       
86 50 F   NV     1 8   1     4.8 300 45 11       1                 1         
87 54 F   NV   1   20       1 2.8 140 66 6.8         1             1           
88 47 F   NV     1 7   1     2.8 250 48 8.8       1                 1 1     1 
89 41 F   NV     1 14 1   1   2.2 98 40 8.4     1                           1 
90 60 M s NV     1 3     1   11 130 154 5.5       1                         1 
91 55 F   NV     1 6     1   2.3 175 66 7.3       1             1   1       1 
92 60 F   NV     1 10   1     2.3 240 42 5.6     1 1               1 1 1     1 
93 60 F t NV 1   1 25       1 2.6 158 45 10           1 1             1     1 
94 42 F   V     1 7   1     2.9 128 41 7                       1 1       1 
95 46 F   NV     1 8     1   2.3 93 68 6     1                   1 1       
96 72 M s NV 1   1 11   1     2.5 120 67 7.3 1       1   1         1 1         
97 40 F   V     1 5   1     2.1 220 60 6                                   
98 52 F   V     1 6   1     2.2 130 40 9.4             1                     
99 38 M   NV 1 1   25 1     1 3.2 80 43 8                       1 1 1       
100 26 M   NV   1   12       1 2.2 140 67 8.8       1                 1       1 
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Master chart of NESRD -DM Patients 
            DIABETES MELLITUS MEDICATION INVESTIGATION ORAL  LESIONS PRESENT IN NESRD 
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1 30 M   NV   1   10         1 117 46 15                         1         
2 21 F   NV   1   15       1 0.8 106 22 11           1                       
3 20 M   NV   1   20       1 1 93 28 14                         1 1       
4 48 M   NV     1 2         1.2 120 32 15 1   1                           1 
5 35 F   V     1 4           110 38 13       1     1                 1 1 
6 44 F   V     1 10         0.9 105 28 12 1   1                   1         
7 32 M   NV   1   14       1 1 185 31 15                   1               
8 23 F   V   1   13       1 0.9 190 30 9       1                           
9 32 M   NV     1 1 1       1.1 289 40 10     1                           1 
10 68 M   V     1 4 1     1 1 260 30 11 1   1 1                           
11 32 F   V   1   5       1 0.7 146 26 11     1 1   1 1           1         
12 70 M s V     1 26       1 0.7 130 36 12             1           1         
13 56 M   V     1 2   1     1.8 202 30 13       1                           
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14 36 F   V 1   1 3         0.8 108 25 11     1                             
15 55 F   NV     1 2         1.1 226 30 11       1                 1 1       
16 44 F   NV     1 2         1 70 30 12                                   
17 38 F   V     1 2         1.4 160 26 13                         1 1     1 
18 73 M s NV     1 15         0.8 90 29 12                         1 1       
19 43 F   NV     1 5         0.7 180 28 12     1                   1       1 
20 65 F   NV 1   1 4       1 1.2 170 30 13       1                           
21 37 M   NV   1   25       1 0.7 185 21 12                 1               1 
22 18 M   NV     1 1         1.2 88 30 11                   1               
23 20 M   V   1   2       1 0.7 213 27 8     1                     1       
24 54 M   V     1 1 1       0.9 192 30 10                               1   
25 50 M   V     1 2         1 150 35 11                                 1 
26 46 F   V     1 4         1.2 152 45 10       1                           
27 42 F   V 1   1 6         0.9 102 29 11                                 1 
28 23 M   V   1   11 1     1 1.1 82 35 12     1                     1     1 
29 70 M s V     1 1         1.4 261 15 15 1                         1     1 
30 15 F   NV   1   7 1     1 0.8 270 34 16           1 1                     
31 49 F   V     1 12         1.1 161 24 16     1 1                         1 
32 52 M s NV     1 1         1.1 268 28 14       1                 1 1       
33 34 F   NV     1 1         1 210 32 16       1             1           1 
34 60 M s NV     1 5       1 1.2 156 46 13             1                     
35 36 M   V   1   25       1 1.2 131 38 13                                   
36 28 F   V     1 1         0.9 82 25 13     1                     1       
37 46 F   V 1   1 2 1       0.9 220 28 13             1           1         
38 31 F   V   1   14 1     1 0.7 175 22 15             1           1         
39 28 F   V   1   10       1 0.8 100 23 12       1     1       1   1         
40 40 F   V     1 3         0.8 170 28 11     1                   1       1 
41 52 M s V     1 2         1.1 293 30 11       1     1       1             
42 36 F   V     1 3       1 1.8 229 40 11                         1       1 
43 27 F   V   1   16   1   1 0.6 132 25 13                         1         
44 24 M   V   1   15         1 208 22 11     1                   1         
45 45 F   V     1 2 1       1 110 30 13                         1       1 
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46 46 F   V     1 1 1       0.9 200 28 13         1               1       1 
47 51 F   V     1 7         0.7 130 25 13                         1       1 
48 60 F   V 1   1 12         1 116 34 13     1                             
49 45 F   V     1           0.6 170 22 11       1             1   1         
50 15 F   V   1   5       1 0.8 105 28 10     1 1   1           1 1 1       
51 27 F   V     1 1         0.8 98 24 10                         1         
52 45 F   V     1 1         0.7 110 27 11                 1       1         
53 22 F   V     1 1       1 0.9 104 28 14                                 1 
54 50 F   V     1 1         0.9 90 28 15     1                   1         
55 35 F   V     1 1         0.9 130 38 16       1             1   1         
56 40 M s V   1   40       1 0.6 108 21 13                                 1 
57 22 F   V   1   2       1 0.8 210 29 12         1               1       1 
58 55 F   V 1   1 1         0.7 160 23 11     1                           1 
59 42 F   NV 1   1 4         0.9 102 29 13       1             1     1     1 
60 82 F   NV 1   1 1         0.9 103 30 12       1             1   1       1 
61 51 F   V     1 4         0.7 318 18 11     1 1                       1 1 
62 25 F   V   1   1       1 1 89 31 11     1                             
63 45 M   V 1   1 4 1     1 0.7 180 25 11     1     1                       
64 38 F   V     1 3 1       1 200 35 13     1                   1         
65 56 F   V     1 3 1       0.7 154 25 15       1   1         1             
66 57 F   V 1   1 6         1 104 25 13                   1               
67 45 F   V     1 1         1 90 30 9     1                   1         
68 59 F   V     1 9       1 1.1 148 27 11                                 1 
69 32 F   V     1 1         0.9 90 22 10       1                           
70 45 M s V     1 2       1 1.1 178 36 12     1                             
71 55 M s V     1 1       1 1.1 92 31 13                                 1 
72 58 F   V     1 6       1 0.9 94 35 12                                 1 
73 27 F   NV     1 3         0.9 74 22 10     1                   1         
74 45 F   V 1   1 6         0.9 96 30 13   1                             1 
75 54 F   V 1   1 2         1 95 21 13     1                   1       1 
76 21 M   V   1   12 1     1 0.7 65 24 14                         1 1       
77 26 M   V   1   12       1 1 83 32 12                         1       1 
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78 19 F   V   1   5       1 1.2 330 32 14                         1         
79 16 M   V     1 2       1 0.7 150 26 13                                 1 
80 15 M   V     1 4       1 0.9 236 30 15                 1               1 
81 60 F t V     1 3         0.8 161 20 12           1                     1 
82 46 F t NV     1 1 1 1     0.6 187 23 11                           1     1 
83 34 M   V     1 1         1 134 28 11     1                   1         
84 66 M s V     1 6         0.9 83 30 11                   1               
85 44 F t V     1 3 1       0.9 210 29 11                                 1 
86 52 M t V     1 8 1       1 135 30 12     1       1           1     1 1 
87 52 F t V     1 3       1 1 120 24 13                                   
88 35 F   V     1 2         1 173 33 12                                 1 
89 24 F   V     1 1         1 78 21 11                                   
90 39 M s V     1 1       1 1.1 104 38 15                         1       1 
91 36 F   V     1 5         1.2 145 21 14     1                             
92 26 M s V 1   1 9       1 0.8 305 16 15                                 1 
93 27 M   NV     1 4       1 0.9 280 30 13                         1       1 
94 56 F t NV     1 3 1       0.7 123 24 12 1                         1       
95 33 F   V     1 2 1 1     0.7 103 25 12       1                           
96 30 F   V 1   1 5   1     0.9 212 29 12                     1   1         
97 50 M   V     1 2 1     1 1.2 220 34 12                                   
98 28 M   V     1 16 1     1 0.8 141 26 12                                   
99 20 F   V     1 4 1 1     1.1 73 28 13                                   
100 70 M s V     1 5 1     1 0.9 132 29 11   1                               
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RAGAS DENTAL COLLEGE & HOSPITAL 
2/102, East Coast Road, Uthandi, Chennai - 600119 
DEPARTMENT OF ORAL MEDICINE & RADIOLOGY 
CASE SHEET PROFORMA 
                                                                                      Date: 
Name: 
Age: 
Sex: 
Occupation: 
Income: 
Address: 
 
 
Phone number: 
Tobacco related habits: 
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Dietary habits: 
Medical history: 
1. Systemic disease: 
2. Diabetes mellitus: 
a) Duration  of diabetes: 
b) Family history: 
c) Medication: 
 
Investigations: 
Serum creatinine level: 
Blood glucose level:   fasting sugar:                      
Serum urea level: 
Oral lesion present: 
 Saburral tongue : 
 Candidiasis: 
 Dry and fissured lips: 
 Petechiae or Ecchymoses: 
 Smooth tongue: 
 Burning tongue: 
 Ulcerative or uremic stomatitis: 
 Annexure II 
 
 
 
169 
 Herpes simplex: 
 Angular cheilitis: 
 Uremic fetor: 
 Xerostomia: 
 Pale mucosa:  
 Other lesions: 
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CONSENT LETTER 
 
I   ……………………, the undersigned hereby given my consent for 
the performance  of diagnostic test on myself to evaluate the incidence of 
oral mucosal lesions in the diabetic patients with  renal disease conducted by 
Dr.B.Senthil under the able guidance of Dr.(Capt.).S.Elangovan ,M.D.S., 
Professor, Department Of Oral Medicine And Radiology, Ragas Dental 
College And Hospital,Chennai-600119. I have been informed and explained 
the status of my disorder ,evaluation procedure, risk involved and likelihood 
of success .I also understand and accept this as a part of the study protocol 
there by voluntarily unconditionally freely give my consent without any fear 
or pressure in mentally sound and conscious state to participate in the study 
 
Witness/representative                                                    Patient signature 
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å․¹î™ ð®õ‥ 
 
----------------------- â¡A¡ø ï£¡, ªê¡¬ù, ó£è£v ð™ 
ñ¼•¶õ‚ è™ÖK ñŸÁ‥ ñ¼•¶õñ¬ùJ¡ õ£… ñ¼•¶õ‥ ñŸÁ‥ 
á´èF˜ ¶¬øJ¡ «ðó£CKò˜ ñ¼.«è․ì¡, âv.Þ÷ƒ«è£õ¡ Üõ˜èO¡ 
«ñŸð£˜¬õJ™, º¶G¬ô(M.D.S) ð†ì․ð®․¹ ðJ½‥ ñ¼.H.ªê‣F™ 
Üõ˜èœ «ñŸªè£œÀ‥, ‧ cKN¾ «ï£ò£OèO¡ CÁcóè «è£÷£ø£™ ãŸð´‥ 
õ£… ê‥ñ‣îñ£ù «ï£…è¬÷ è‡ìPî™  â¡A¡ø Ýó£…„C‚è£ù 
ðK«ê£î¬ùèÀ‚° â¡¬ù à†ð´•¶õîŸ° âù¶ ñùºõ‣î ðKÌóí 
ê‥ñ•F¬ù ÜO‚A«ø¡. «ñ½‥ âù‚° â¡Â¬ìò «ï£J¡ î¡¬ñ¬ò․ 
ðŸP»‥, Üîù£™ ãŸðì‚ Ã®ò M¬÷¾è¬÷․ ðŸP»‥ â´•¶‚ 
Ãø․ð†´œ÷¶ âù¾‥, Þ‣î ðK«ê£î¬ù‚° ï£¡ â‣îMî Ü„êºI¡P 
î¡Q„¬êò£è¾‥, ªîOõ£ù º¿ ñù¶ì¡ â¡Â¬ìò ðKÌóí 
ê‥ñî•F¬ù ÜO‚A«ø¡ âù Þî¡ Íô‥ ªîKò․ð´•¶A«ø¡. 
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